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ABSTRACT
Proteins that belong to TRIM family are characterized by the presence of 
the tripartite motif module, composed of a RING domain, one or two B-box 
domains and a Coiled-coil region. TRIM proteins are involved in several 
cellular processes such as apoptosis, cell cycle regulation and viral response. 
The aim of my project was to study the involvement of TRIM proteins in the 
ubiquitylation process, a versatile post-translational modification mechanism 
used by eukaryotic cells mainly to control proteins levels through 
proteasome-mediated proteolysis. In particular, the presence of the RING 
domain and experimental data suggested a possible TRIM role as Ubiquitin 
Ligases (E3), the component of the ubiquitylation cascade responsible for the 
transfer of Ubiquitin to the specific target.
A condition for being an E3 is the interaction with another component of 
the ubiquitylation cascade, the Ubiquitin Conjugating Enzymes (UBE2). 
Therefore, I tested the interaction between 26 UBE2 enzymes and 42 TRIM 
proteins. I observed that the majority of the TRIM proteins tested interact 
with UBE2 enzymes and I also found a general preference of the TRIM 
proteins for the D and E classes. Two important exceptions were observed: 
TRIM9-UBE2G2 and TRIM32-UBE2V1/2 specific interactions. Furthermore, 
representative interactions were confirmed and I also demonstrated that the 
TRIM E3 activity is only manifest with the UBE2 they interact with. For most 
specific interactions I could also observe subcellular co-localisation of the 
TRIM involved and its cognate UBE2 enzyme suggesting that the specific 
selection of TRIM-UBE2 pairs has physiological relevance.
In addition I found that almost all TRIM proteins tested interacted with 
UBE2I that is the specific E2 enzyme involved in modification with 
SUMO, a Ubiquitin-like peptide. Consistently, representative interactions 
were confirmed and for a subset of TRIM proteins I demonstrated the
1
involvement in the SUMOylation pathway suggesting a possible cross-talk 
between ubiquitylation and SUMOylation.
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CHAPTER 1: INTRODUCTION
1.1 Ubiquitylation
Ubiquitylation is a form of post-translational modification of proteins 
in eukaryotes in which ubiquitin, a highly evolutionary conserved 76-residue 
polypeptide, is linked to target proteins (Hershko, Heller et al. 1983). 
Ubiquitylation of proteins is achieved through an enzymatic cascade 
involving Ubiquitin Activating Enzyme (El), Ubiquitin Conjugating Enzyme 
(E2) and Ubiquitin Ligase (E3). An additional Ubiquitylation factor, whose 
name is E4, can sometimes induce the synthesis of long multiubiquitin chains 
(Koegl, Hoppe et al. 1999). The fate of the ubiquitylated proteins depends on 
the type of modification received. During ubiquitylation, ubiquitin chains or 
single ubiquitin molecules are linked to target proteins, giving rise to poly- or 
monoubiquitylation respectively. Polyubiquitylation generally targets proteins 
for degradation by the proteasome; instead, monoubiquitylation is implicated 
in endocytosis, endosomal sorting and histone regulation (Sun and Chen 
2004). However, in some cases (i.e. K63 polyubiquitin chain) poly­
ubiquitylation also has non-proteasomal regulatory functions like targeting 
proteins to nucleus, cytoskeleton and endocytic machinery, or modulating 
enzymatic activity and protein-protein interactions (see paragraph 1.3).
The ubiquitylation process starts with the synthesis of ubiquitin as a 
larger peptide that must be processed to reveal the C-terminal Glycine (Gly) 
residue, which will be the site of attachment of target molecules. This 
processing is carried out by Deubiquitylation enzymes (DUB) that also 
remove ubiquitin from modified substrate (Wilkinson 1997). The E l enzyme 
initiates the cascade by catalyzing adenylation of the ubiquitin, by forming an 
acyl-phosphate linkage with AMP. The catalytic cysteine (Cys) of E l attacks 
Ubiquitin'-AMP complex, releasing AMP and forming a thioester linkage 
between the El catalytic Cys and the ubiquitin C-terminus (Figure 1).
Ubiquitin is then transferred to an E2, again through a thiol-ester linkage. E3s, 
which are primarily responsible for assuring specificity to ubiquitin 
conjugation, interact with the ubiquitin-charged E2 and the substrate, 
facilitating the formation of isopeptide bonds between the C-terminus of 
ubiquitin and lysines (Lys) on the target protein (Figure 1).
To date, eukaryotic genomes have been found to encode two or at most 
a few Els; a great number of E2s exists, at least 11 in yeast and over 35 in 
human (van Wijk and Timmers 2010). Instead, the diversity and number of 
proteins that are regulated by ubiquitylation predict the existence of 600- 
1,000 E3s (Ardley and Robinson 2005). This allows modification of many 
proteins in a highly specific manner, and such modifications are often under 
temporal and spatial control.
The ubiquitylation process creates specific and reversible switches between 
different functional states of a substrate protein, allowing the fine control of 
numerous cellular pathways.
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Figure 1
(Hochstrasser 2009)
Model of E3 protein-mediated ubiquitin or ubiquitin like modification. The E3-E2 substrate unit can 
assemble to form larger complexes that may contain several ubiquitylation pathway components. The 
ubiquitylation or ubiquitin like modification factors are distributed within the cells as discrete 
compartments that participate in different pathways.
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1.2 Ubiquitylation machinery: E l, E2 and E3
1.2.1 Ubiquitin-Activating Enzyme (El)
The main function of the Ubiquitin-Activating Enzyme (El) is to 
catalyse the adenylation of ubiquitin at the expense of an ATP molecule. The 
resulting adenylated-ubiquitin is transferred to the active site cysteine (Cys) 
of El through the formation of a thioester bond; then, ubiquitin is transferred 
to the active site Cys of the Ubiquitin Conjugating enzyme (UBE2), the next 
enzyme in the ubiquitylation cascade.
The El enzyme is highly conserved in plants (Hatfield, Callis et al.
1990), in humans (Handley, Mueckler et al. 1991) and in yeast where it plays 
a critical role since the deletion of yeast E l, UBA1, is lethal (McGrath, 
Jentsch et al. 1991). In human, two E l enzymes are known to initiate 
ubiquitin conjugation: UBA1 and UBA6. Even if they are distantly related 
(about 40% identity), they share a common structure. They contain three 
domains: an adenylation domain composed of two ThiF -homology motifs 
(Lake, Wuebbens et al. 2001), which binds ATP and Ubiquitin; the catalytic 
Cys domain (CCD), which is the acyl carrier for ubiquitin; the C-terminal 
ubiquitin-fold domain which binds the UBE2 enzymes. Interestingly, Jin et al. 
(Jin, Li et al. 2007) demonstrated that UBA1 and UBA6 interact with the 
UBE2 enzymes in a specific manner. They examined E l specificity in UBE2 
charging in a panel of 29 UBE2s and they found that some UBE2 interacted 
with both UBA1 and UBA6, but some others interacted with either UBA1 or 
UBA6.
In addition to their chemical roles in initiating ubiquitin conjugation 
cascade, E l enzymes also establish specificity by matching ubiquitin or 
Ubiquitin-like peptide (UBL, see paragraph 1.4) with specific E2s. For 
examples UBA1 enzyme is able to recognize the C-terminal tail residue 72 in 
ubiquitin and to distinguish it from the same residue of the other Ubiquitin-
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like peptides (Arg in ubiquitin and, for example, Ala in NEDD8). Rules for 
how this specificity is achieved are only beginning to emerge, but it is clear 
that specificity is achieved at multiple levels (Schulman and Harper 2009).
Moreover, UBA1 enzyme is regulated by phosphorylation and proposed 
roles of UBA1 phosphorylation include increasing nuclear import and/or 
retention, and modulation of nucleotide excision repair during macrophage 
differentiation (Stephen, Trausch-Azar et al. 1996; Nouspikel and Hanawalt 
2006). Furthermore, distinct isoforms of UBA1 display different subcellular 
localizations (Grenfell, Trausch-Azar et al. 1994) although the functions of 
different UBA1 modifications and isoforms remain poorly understood.
1.2.2 Ubiquitin Conjugating Enzyme (UBE2)
The ubiquitin peptide, after being activated by E l, is transferred to a 
Ubiquitin Conjugating Enzyme (UBE2) cysteine (Cys) residue as a thioester 
and from there, in an E3-dependent manner, to the substrate (Hershko, Heller 
et al. 1983). Eleven UBE2 enzymes have been identified in the yeast genome 
(Ubcl-8, 10, 11, 13). Two additional enzymes, Ubc9 and Ubcl2, are specific 
for the ubiquitin-like proteins Smt3 and Rub-1, respectively (Glickman and 
Ciechanover 2002). Many more E2s have been described in higher organisms. 
Typically, in humans 38 different UBE2 proteins were found that are broadly 
grouped into four classes, all of which are distinguished by the presence of a 
Cys-catalytic core domain (UBC): class I enzymes consist of just the UBC 
domain; class II possess a UBC and a C-terminal extension; class III possess a 
UBC and an N-terminal extension; and class IV possess a UBC and both bl­
and C-terminal extensions. These extensions appear to be important for some 
subfamily function, including E2 localization and protein-protein interactions. 
Ubiquitin E2 variant (UEV) proteins also have a UBC domain but lack the 
active-site Cys residue (Sancho, Vila et al. 1998).
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The first important task of an UBE2 protein is to ensure that it receives 
ubiquitin, but not related Ubiquitin-Like peptides (UBLs) on its active site. 
The only exception to this role is UbcH8/UBE2L6 since it can conjugate both 
ubiquitin and ISG15, an ubiquitin-like peptide (Durfee, Kelley et al. 2008). 
Although E ls and E2s for UBLs have a structure similar to those of the 
corresponding enzymes for ubiquitin, E2s for ubiquitin specifically interact 
with the two E ls of the ubiquitin pathway. Biochemical and structural 
analyses revealed that E2s bind E ls with high affinity only if the E l is 
carrying their modifier. Moreover, the charging of an El with ubiquitin 
changes conformation of the El exposing cryptic E2 binding sites allowing 
the formation of the proper E1-E2 complex (Huang, Hunt et al. 2007)
After being charged with ubiquitin, E2s engage E3s to catalyse 
substrate ubiquitylation. E2 enzymes act via selective protein-protein 
interactions with the E l and E3 enzymes and connect activation to covalent 
modification. By doing so, E2s differentiate effects on downstream substrates, 
either with a single Ub/UBL molecule or as a chain. Indeed, while E3s are 
involved in substrate selection, generally E2s are the main determinants for 
selection of the Lysine (Lys) to build different ubiquitin chains (Kim, Kim et 
al. 2007). It has been well established that for example the UBE2D family of 
E2s, UBE2G2, cdc34 (cell division cycle 34) and UBE2K mediate Lys48- 
linked polyubiquitin chain formation that mark protein for degradation via 
proteasome (Li, Tu et al. 2007) ; whereas, UBE2N and UBE2V1/V2 protein 
mediate the assembly of Lys63-linked poly-Ub chains that play a regulatory 
role in diverse signalling pathways in a non proteolytic fashion (McKenna, 
Spyracopoulos et al. 2001)
Moreover, in addition to cycling between E ls and E3s, some E2s bind 
cofactors that influence their localization, activity or specificity. This is best 
understood for the yeast coupling of ubiquitin conjugation to ER degradation 
protein 1 (Cuel), a transmembrane protein of the ER that uses a C-terminal 
motif to recruit UBE2G2 (Chen, Mariano et al. 2006). The association with
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Cuel also increases the ubiquitylation activity of UBE2G2 and protects it 
from autoubiquitylation and proteasomal degradation. These properties allow 
Cuel to focus UBE2G2 activity on substrates at the ER membrane and, 
moreover, Cuel is required for UBE2G2-dependent ER-associated 
degradation (ERAD).
The nomenclature of the different E2 enzymes is confusing, and similar 
terms given to yeast and mammalian enzymes do not reflect functional or 
structural homology. When the first E2 genes were cloned researchers mostly 
used the form E2-nK (where n denotes the molecular weight of the E2) and 
UBCn in yeast or UBCHn in humans (where n corresponds to the order of 
discovery). Other E2s were labelled following their discovery in genetic or 
proteomic screens, without a reference to their E2 function, for example 
Huntingtin-interacting protein 2 (HIP2; also known as E2-25K, UBCH1 and 
UBE2K). As a result, E2s from different organisms bearing the same number 
are often not functionally related, and most E2s have multiple names. Thus 
human UBCH1 (Kaiser, Mansour et al. 1994) is not the human homolog of 
yeast Ubcl, but rather the homolog of yeast Ubc2/Rad6. Yeast ER Ubc6 and 
Ubc7 are not the homologs of human UbcH6 and UbcH7 that are soluble 
enzymes involved in targeting of soluble proteins in the cytosol (Nuber, 
Schwarz et al. 1996).
1.2.3 Ubiquitin Ligase (E3)
The Ubiquitin Ligases (E3) are responsible for bringing the ubiquitin- 
charged E2 enzymes, through binding, in close proximity to the specific 
substrate allowing the correct transfer of the ubiquitin moiety. The E3s act as 
single proteins or protein complexes that bind both the Ubiquitin-charged E2 
and the substrate. In most cases (i.e., RING domains E3s, see below), the E3s 
serve as scaffold that bring both the E2s and the substrate. In other cases (i.e., 
HECT domain E3, see below), the activated ubiquitin is transferred from E2
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to an internal cysteine (Cys) residue on E3 before conjugation of ubiquitin to 
an e-NH2 group of an internal lysine (Lys) residue in the target. Less 
commonly, ubiquitin is conjugated to the terminal amino group of the 
substrate (Ciechanover and Ben-Saadon 2004) or even to Cys side chains via 
a thioester bond (Cadwell and Coscoy 2005). For its activity, the E3 ubiquitin 
ligase uses protein-protein interaction domains outside the catalytic domain to 
bind the substrate.
Because of lack of significant homology among the ligases initially 
identified, it was thought that they belong to a large number of protein 
families. Recently, it has become clear that even though E3s are 
heterogeneous, they can be classified into two major groups, in relation to 
their architecture: HECT domain E3 enzymes and four classes of RING finger 
E3 ubiquitin ligases: the SCF, VBC and anaphase-promoting (APC) 
complexes, and single-polypeptide RING-finger E3 enzymes (Figure 2).
1 . HECT domain E3
The HECT domain protein family was originally identified by 
sequence similarity to the C-terminal region of E6-AP, an E3 ubiquitin ligase 
required for ubiquitylation of the tumour suppressor protein p53 induced by 
the E6 oncoprotein of HPV virus (Huibregtse, Scheffner et al. 1995). In 
contrast to the RING domain E3s, HECT domain E3s directly catalyze 
protein ubiquitylation. Ubiquitin-charged E2 enzymes directly transfer 
ubiquitin to the active-site cysteine (Cys) within the HECT domain in a 
transthiolation reaction, preserving the high-energy ubiquitin thioester bond. 
Substrate ubiquitylation occurs by nucleophilic attack of the E3-ubiquitin 
thioester bond by a lysine side chain of the target protein, although the 
mechanism of polyubiquitylation is still unclear (Huibregtse, Scheffner et al. 
1995).
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Structural information is available for the HECT domains of human 
E6AP/Ube3A(Huang, Kinnucan et al. 1999), WWP1 (Verdecia, Joazeiro et 
al. 2003) and Smurf2 (Ogunjimi, Briant et al. 2005). All HECT E3s have an 
N-terminal domain, which varies among the different HECT domain proteins 
and is involved in specific substrate recognition (Schwarz, Rosa et al. 1998), 
and a catalytic C-terminal domain (i.e. the HECT domain) that is divided into 
an amino terminal lobe (N lobe) and a carboxyl-terminal lobe (C lobe). In 
details, the N lobe is about 250 amino acids and contains the E2 binding site; 
while the C lobe consists of 100 amino acids and contains the active-site 
cysteine required for the transthiolation reaction (Eletr and Kuhlman 2007). 
Interestingly, it is known that HECT E3s have a different specificity for 
UBE2 binding. For example, E6AP binds UbcH7/UBE2L3 and the closely 
related UbcH8/UBEL6 in a specific manner (Schwarz, Rosa et al. 1998) 
whereas Saccharomyces cerevisiae Rsp5, which share the domain 
organization with nine human HECT E3 (i.e. NEDD4 or Itch/AIPA), binds 
only UbcH5 and UbcH6 (Schwarz, Rosa et al. 1998). However, an important 
feature of HECT E3 ligase is that the identity of the E2 did not influence the 
type of ubiquitin chains formed by HECT E3s. In contrast with E2/RING E3 
complex where the identity of the E2 has clearly been shown to determine the 
type of chains formed (Kim and Huibregtse 2009), the only essential function 
of the E2 in the HECT model is to transfer ubiquitin to the HECT E3 ligase. It 
has been demonstrated that different HECT E3s have specificities for the 
types of polyubiquitin chains that they synthesize. For example, E6AP is 
highly specific for catalysis of K48-linked polyubiquitylation (Wang and 
Pickart 2005); human KIAA10 HECT E3 preferentially catalyzes K48 and 
K29 linkages (Wang, Cheng et al. 2006). In contrast, Saccharomyces 
cerevisiae Rsp5 preferentially synthesizes K63 chains in vitro and in vivo 
(Kim and Huibregtse 2009). Recently, Kim and Huibregtse (2009) have 
demonstrated that the determinants of HECT E3 ligases for chain type 
specificity are within the last -60 amino acids of the C lobe.
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To date, 28 proteins have been found to belong to HECT E3s family 
and it is relevant that, in addition to ubiquitylation, they regulate the 
trafficking of many receptors, channels, transporters and viral proteins. This is 
the reason for which they play an important role in sporadic and hereditary 
human diseases including cancer, cardiovascular (Liddle’s syndrome) and 
neurological (Angelman syndrome) disorders (Scheffner and Staub 2007).
2. RING motif-containing E3s
The RING motif was first identified in the early 1990s in the protein 
encoded by the Really Interesting New Gene 1 (Freemont, Hanson et al.
1991). The canonical RING consensus sequence has been defined as Cys-X2- 
Cys-X9.39 -Cys-X1_3-His-X2 _3 -Cys/His-X2 -Cys-X4 _4 8-Cys-X2-Cys, where X can 
be any amino acid residue (Borden 2000). Three-dimensional structures of 
RING domains revealed that its conserved cysteine (Cys) and histidine (His) 
residues are buried within the domain’s core, where they help maintaining the 
overall structure through coordination of two atoms of zinc. The RING 
domain binds two Zn2+ ions in a unique “cross-brace” arrangement, which 
distinguishes it from tandem zinc fingers and other similar motifs (Borden 
2000). Unlike zinc fingers, the zinc coordination sites in a RING domain are 
interleaved, yielding a rigid, globular platform for protein-protein interaction, 
hence RING domain (Freemont, Hanson et al. 1991). To date, numerous 
RING variants have been discovered, including two important classes: RING- 
HC and RING-H2. The classification depends on whether there is a Cys or a 
His in the fifth of the eight Zn2+ coordinating sites. The B-box domain of the 
TRIM subfamily of RING E3s (see paragraph 1.5) and the U-box domain (see 
below) are structurally related to the RING. However, whether such 
consensus sequence variations have functional relevance remains unclear.
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RING finger proteins possess ubiquitin ligase activity by themselves or 
as a part of multisubunit E3s by directly binding ubiquitin-conjugating 
enzymes (UBE2) (Deshaies 1999; Lorick, Jensen et al. 1999). The precise 
nature of RING-E2 interaction has been first probed by the NMR analyses of 
BRCA1 and CNOT4 complexed with UbcH5/UBE2D (Brzovic, Keeffe et al. 
2003; Dominguez, Bonvin et al. 2004). Moreover, the crystal structure of c- 
Cbl RING domain bound to UbcH7/UBE2L3 together with mutational 
analyses highlighted residues on the RING and UBE2 that play a crucial role 
in sustaining the interface. It is clear that the loop regions comprising the zinc 
coordination sites of the RING domain and the central helix that connects the 
first and the second coordination sites together form a cleft on the surface of 
the RING to which E2s bind (Zheng, Wang et al. 2000). X-ray and NMR data 
highlighted that Ile383 and Trp408 of c-Cbl and equivalent residues in other 
RING proteins have been consistently implicated in the interaction with 
UBE2s. Even if functional studies of the RING E3s typically employ 
mutations in the zinc-binding residues to inactivate the RING domain, 
mutation of the lie and Trp amino acid residues in c-Cbl, CNOT4 and other 
RING E3s eliminate RING-E2 interaction and E3 ubiquitin activity (Joazeiro, 
Wing et al. 1999; Albert, Hanzawa et al. 2002)
Interestingly, as already observed for HECT E3/UBE2 interactions 
(see above), RING E3/UBE2 interactions occur in a specific way. It has been 
proven that RING E3s that interact with UbcH7/UBE2L3 and the related 
UbcH8/UBE2L6 cannot interact with UBE2D/E family members (Moynihan, 
Ardley et al. 1999; Martinez-Noel, Muller et al. 2001). To date, even if many 
examples are known to sustain this thesis (i.e. Cbl/UBE2L3 or 
CNOT4/UBE2D exclusive binding) there is not enough information about 
RING amino acid residues assuring specificity to RING E3/E2 interaction.
Many RING finger proteins possess ubiquitin ligase activity by 
themselves or as a part of multisubunit E3s (Deshaies 1999). Certain 
members, Mdm2 (Boyd, Tsai et al. 2000; Geyer, Yu et al. 2000), Ubrl/E3a
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(Kwon, Reiss et al. 1998), and Parkin (Shimura, Hattori et al. 2000), for 
example, are monomers or homodimers and contain both the RING finger 
domain and the substrate-binding/recognition site in the same molecule. 
Many others are part of multisubunit complexes; among them are the APC 
involved in the degradation of cell cycle regulators (Page and Hieter 1999), 
the von-Hippel-Lindau-Elongins B and C (VBC)-Cul2-RING finger complex 
(Iwai, Yamanaka et al. 1999; Lisztwan, Imbert et al. 1999) involved in the 
degradation of H IFl-a (Ivan M et al., 2001) and the Skpl-Cullin/Cdc53-F- 
box protein (SCF)-RING finger complexes involved in degradation of signal- 
and cell cycle-induced phosphorylated proteins (De Sepulveda, Ilangumaran 
etal. 2000).
3. E4/U box-containing proteins
E4 defines a protein family that shares a modified version of the RING 
finger motif. The predicted three-dimensional structure of the U-box is similar 
to that the RING finger, despite the lack in the former of the hallmark metal- 
chelating residues present in the latter (Aravind and Koonin 2000). The 
prototype U-box protein, Saccharomyces cerevisiae Ufd2, was originally 
described as an ubiquitin chain assembly factor (also known as E4) that 
promotes the polyubiquitylation of artificial fusion proteins in conjugation 
with E l (Ubal), E2 (Ubc4) and E3 (Ufd4, a HECT-type E3 enzyme) (Koegl, 
Hoppe et al. 1999). It has been highlighted that E4 is required for further 
elongation of an oligoubiquitin chain of certain substrates and the resulting 
polyubiquitin proteins are then recognized by the 26S proteasome for 
degradation.
The observation that U-box is a derived version of RING motif 
suggested that possibility that U-box could also function as E3 enzymes. 
Indeed, Jiang and coworkers (2001) showed that CHIP, a U-box protein,
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functions as an E3 ubiquitin ligase (Jiang, Ballinger et al. 2001). More 
recently Xu and coworkers (2008) resolved both CHIP/UbcH5 and 
CHIP/Ubcl3 crystal structures, showing that CHIP interaction with these two 
different enzymes results in the formation of different types of polyubiquitin 
chains as already observed for the other E3 ligases (Xu, Belunis et al. 2003; 
Xu, Kohli et al. 2008). Moreover, the E3 ligase activity has been 
demonstrated for all six mammalian members so far identified (Hatakeyama, 
Yada et al. 2001). Thus, it seems that U-box proteins possess E3 activity and 
that their E4 activity likely represents a specialized type of E3 activity 
apparent with oligoubiquitylated artificial fusion proteins as substrate.
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A comparison of ubiquitin ligases. HECT domain E3 ligases transiently accept ubiquitin from the 
UBE2, in a thiolester linkage, before transferring it to the substrate (left branch of the pathway). 
RING and U- box containing E3 ligases facilitate direct transfer of the ubiquitin from the UBE2 to the 
substrate (right branch of the pathway). SCF complex (Skpl-Cullin-F box) is a prototype of 
multisubunit complex RING E3 ligases. Cullins serve as a scaffold to bind a RING finger protein, 
R ocl/R bxl, to a specific E2.
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1.3 Role of Ubiquitylation
Substrate proteins can be modified by ubiquitin in different ways. A 
single ubiquitin may be conjugated to a single Lysine (Lys) residue of the 
substrate (monoubiquitylation) or multiple ubiquitins can be linked via one of 
the seven Lys residues of the ubiquitin to form short oligoubiquitin chains (2- 
to 4-ubiquitin moieties) or long polyubiquitin chains (>4-ubiquitin moieties). 
The chains can be either linear or branched, where two ubiquitin molecules 
are linked to a single ubiquitin. However the biological significance of this 
type of linkage is still unclear.
Distinct ubiquitin modifications define different biochemical fates. For 
example, monoubiquitylation is involved in the DNA repair, endosomal 
sorting, histone regulation, virus budding and nuclear export; whereas Lys48- 
and Lys 11-linked polyubiquitin chains target proteins for the degradation by 
the 26S proteasome. Lys63-linked polyubiquitin chain has recently emerged 
as a novel post-translational modification of remarkable functional interest for 
its involvement in the DNA repairs and fine-tuning signal transduction 
pathway. It is known that Lys63-linked polyubiquitin chain creates docking 
sites for scaffold proteins involved in the regulation of nuclear factor-xB (NF- 
xB) and mitogen-activated protein kinase (MAPK) pathways. These 
biochemical routes are of great relevance in the response of the immune 
system against pathogens and in inflammation. Instead, much less is known 
about the precise function and topology of chains that are linked through 
Lys6, Lys27, Lys29 and Lys33 and structural analysis are needed to 
understand if these chains also have peculiar conformational properties 
(Figure 3).
The nature of ubiquitin conjugation by E2/E3 complexes is critical 
because the outcome of ubiquitylation is generally determined by the 
topology of the conjugate. In particular, whereas target protein selectivity is 
provided by the E3, E2 determines the specificity for the lysine residue of the 
acceptor ubiquitin in polyubiquitin chains formation mediated by RING and
22
U-box E3, but not by HECT E3s (Kim, Kim et al. 2007). E2s that direct 
specificity for Lys48-polyubiquitin chains are, for example, human Cdc34 or 
UBE2K, while the formation of the Lys63-polyubiquitin chains requires a 
heterodimer composed of Ubcl3/UBE2N and either UBE2V1 or UBE2V2 
(Thrower, Hoffman et al. 2000). Several examples have been described where 
a single RING can recruit different E2s that have different linkage 
specificities. In each case, the output of the reaction is defined by the known 
specificity of the E2 (Christensen, Brzovic et al. 2007; Kim, Kim et al. 2007).
The formation of polyubiquitin chains needs two steps: substrate 
(mono)ubiquitylation and chain elongation (polyubiquity lation). 
Monoubiquitylation seems to lack an inherent specificity for a particular 
lysine residue on the substrate, whereas chain elongation occurs on a 
particular Lys residue of ubiquitin, for example Lys48 or Lys63. 
Nevertheless, the details of polyubiquitin chain formation remain elusive 
(Hochstrasser 2006). A major unanswered question concerns how the 
decision is made by the ubiquitin machinery as to whether mono- or 
polyubiquitylate a substrate. One possibility is that different subsets of 
ubiquitin ligases have specificity for the two different modifications. For 
example, the ubiquitin ligase Mdm2 mediates monoubiquitylation of p53, 
whereas p300 has been suggested to promote p53 polyubiquity lation 
(Grossman, Deato et al. 2003). Alternatively, an individual ubiquitin ligase 
might mediate either mono- or polyubiquitylation, depending on the nature of 
the substrate or other molecular specifiers. Recently, a role for ubiquitin- 
interacting domains (such as the ubiquitin-interacting motif, UIM, or the 
Cuel-homologous domain, CUE) in the determination of monoubiquitylation 
of endocytic proteins has been proposed based on the frequent 
monoubiquitination of proteins containing these domains (Polo, Confalonieri 
et al. 2003).
23
Figure 3
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Examples of different ubiquitin chains. Substrate proteins can be modified with a single ubiquitin 
(mono-ubiquitylation) or multiple (multi mono-ubiquitylation) sites with different fate. Alternatively, 
substrates can be modified either with a chain of ubiquitin molecules (polyubiquitylation) linked to one 
of the seven Lys residues or with an Ubiquitin chains containing branches.
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1.3.1 The Ubiquitin-proteasome system.
The Ubiquitin-proteasome system (UPS) leads to the degradation of the 
proteins by two discrete and successive steps: tagging of the substrate by 
covalent attachment of multiple ubiquitin molecules and degradation of the 
tagged protein by the 26S proteasome complex with the release of free and 
reusable ubiquitin.
The proteasome is a large ATP-dependent proteolytic complex that 
mediates the degradation of most short-lived proteins that control cell cycle, 
transcription, DNA repair, apoptosis and other cellular processes. The 
proteasome is also responsible for the degradation of abnormal or damaged 
proteins and therefore plays an important role in quality control. The 26S 
proteasome is a 2.5 MDa protein complex consisting of two subcomplexes: 
the catalytic 20S core particle (CP or 20S proteasome) and the 19S regulatory 
particle (RP, also known as 19S proteasome or PA700 (Groll, Ditzel et al. 
1997; Nickell, Beck et al. 2009). The CP is a barrel-shaped structure of a 
stack of four seven-subunit rings in a a 7|37|37a 7 configuration (Figure 4). Both 
exterior rings contain one set of seven different a  subunits; and both interior 
rings contain one set of seven different (3 subunits. The CP performs three 
types of catalytic activities inside its chamber: chymotrypsin-like, trypsin-like 
and caspase-like activities that are provided by (35, (32 and (31 subunits, 
respectively (Heinemeyer, Fischer et al. 1997).
Cristal structures of the CP from archaeon, yeast and mammals have 
been solved (Unno, Mizushima et al. 2002). There is a very narrow pore or 
gate at the centre of the a  subunit ring where protein substrates enter the CP 
chamber. The gate is closed in a free CP by interactions among the N-termini 
of the a  subunits blocking substrate entry into the proteolytic chamber. Either 
a  subunits can be “capped" by a 19S regulatory subunit that can be further 
dissected into two multisubunit structures: the “base” that binds directly to the 
a  ring of the 20S core particle, and the “lid” where polyubiquitin is bound 
(Figure 4). The “base” consists of six AAA+ ATPases (Rptl-6) and three
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non-ATPase subunits (Rpnl, Rpn2 and Rpnl3), whereas the “lid” includes at 
least nine non-ATPase subunits (Rpn3, Rpn5-9, R pnll, Rpnl2 and 
Rpnl5/Seml) whose enzymatic activity is still unknown. An alternative form 
of regulatory subunit called the 1 IS particle can associate with the core in 
essentially the same manner as the 19S particle; the 1 IS may play a role in 
degradation of foreign peptides such as those produced after infection by a 
virus (Figure 4).
The 19S regulatory particle is responsible for recognizing ubiquitylated 
proteins and other potential substrates of the proteasome. Then, the 19S 
regulatory ATPases open the gate in the 20S that blocks the entry of 
substrates into the degradation. The mechanism by which the proteasomal 
ATPases open this gate, has been recently clarified by David M. Smith and 
collaborators (Smith, Chang et al. 2007). The 19S ATPases contain a 
conserved C-terminal hydrophobic-tyrosine-X motifs (HbYX) that are 
essential for 19S to associate with the 20S and open its gated-channel for 
substrate entry. Upon ATP binding, these C-terminal residues bind to pockets 
between the 20S a-subunits, and tether the ATPase complex to the 20S 
proteolytic complex thus joining the substrate unfolding equipment with the 
20S degradation machinery. Binding of these C-termini into these 20S 
pockets by themselves stimulates opening of the gate in the 20S much like a 
"key-in-a-lock" opens a door (Smith, Chang et al. 2007; Rabl, Smith et al.
2008). Also, because the 20S particle's central channel is narrow and gated by 
the N-terminal tails of the a  ring subunits, the substrates must be at least 
partially unfolded before they enter the core. The passage of the unfolded 
substrate into the core is called translocation and necessarily occurs after 
deubiquitylation. After degradation of the substrate, short peptides derived 
from the substrate are released, as well as reusable ubiquitin.
The ubiquitin-mediated proteolysis of a variety of cellular proteins 
plays an important role in many basic cellular process like cell cycle, 
differentiation and development, involvement in the cellular response to stress
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and extracellular effectors, morphogenesis of neuronal networks, DNA repair, 
regulation of the immune and inflammatory responses. Moreover, the UPS is 
intricately involved in protein localization and membrane trafficking (Hicke 
2001). The list of cellular proteins that are targeted by ubiquitin is growing 
rapidly; among these are cyclins, cyclin-dependent kinase inhibitors, tumor 
suppressors as well as cell surface receptors and endoplasmic reticulum (ER) 
proteins. Thus, it is not surprising that aberrations in the ubiquitin system 
have been implicated in the pathogenesis of many inherited and acquired 
human pathologies as well as neurodegenerative disease (Ciechanover, Orian 
etal. 2000).
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Formation of the 26S proteasome. The 26S proteasome is a multicatalytic protease that is found in the 
cytosol, perinuclear regions and nucleus of eukaryotic cells. It consists of a 28-subunit catalytic core — 
20S proteasome (2,100 kDa) — which is an assembly of two outer and two inner heptameric rings 
stacked axially to form a hollow cylindrical structure in which proteolysis occurs. The outer rings 
comprise seven different K-subunits that serve as an anchor for the multisubunit ATPase-containing 
PA700 regulator that binds to form a complex referred to as the 26S proteasome.
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1.ERAD
The UPS was thought initially to degrade only cytosolic proteins. 
Recent evidence suggest that substrates for ubiquitylation and subsequent 
degradation are found throughout the cell, in the cytosol, nucleus, ER lumen, 
and membrane, and cell surface membrane (Bonifacino and Weissman 1998). 
Normally, ER membrane proteins or proteins that cross the ER membrane are 
either retained in the ER or traverse the ER lumen to their final destinations: 
the Golgi apparatus, cell surface membrane, extracellular environment and the 
lysosomal system. The ER is equipped with a stringent quality control system 
that monitors the proteins that are synthesized and folded in the ER. This ER 
quality control system (ERQC) is able to discern between the correctly folded 
proteins that exit the ER en route to their final destinations and the misfolded 
or unfolded proteins that are retained and refolded in the ER. Proteins that are 
terminally misfolded are selectively transported from the ER into the cytosol, 
and subsequently ubiquitylated and degraded by the proteasome, a process 
called ER-associated degradation (ERAD). During ERAD, misfolded proteins 
are delivered to 26S proteasome, which resides in the cytoplasm. The 
destruction of ERAD substrates requires polypeptide recognition, delivery 
from the ER to the cytoplasm (termed “retrotranslocation or dislocation”) and 
in most cases ubiquitylation, which ensures efficient delivery to the 
proteasome. Intense interest has been focused on identification of the protein 
conduction channels through misfolded proteins can be transported from ER 
to the cytosol. Early studied suggested that Sec61, the import channel for 
proteins into the ER, might also be the retrotraslocon through which this 
dislocation is effected (Plemper, Bohmler et al. 1997). Another such 
candidate is Derlin-1, a poly topic protein implicated in the targeting of 
several substrates for degradation (Lilley and Ploegh 2004) (Ye, Shibata et al.
2004) In addition, ER-resident ubiquitin ligases such as Hrdl have been 
suggested to form part of this channel (Carvalho, Goder et al. 2006)
In mammalian cells, similar but distinct ERAD components direct the
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translocation of misfolded proteins from the ER to the cytosol for degradation 
via the ubiquitin-proteasome system. Although the degradation pathway of 
ERAD substrates traverses the “canonical” E1/E2/E3 proteasomal route, it is 
nevertheless equipped with unique components essential for the retrograde 
transport. For example, there are two mammalian homologs for each of the 
yeast enzymes Ubc6 and Ubc7, which are responsible for ERAD in yeast: 
UBE2J1 and UBE2J2, mammalian homologs of Ubc6, and UBE2G1 and 
UBE2G2, mammalian homologs of Ubc7. The formers have hydrophobic 
sequences at their C termini that mediate post-traslational insertion into the 
ER membrane; the latter are cytosolic proteins. To date, there is little 
evidence implicating UBE2G1 in ERAD; instead, UBE2G2 is strongly 
implicated in ERAD, functioning with multiple ERAD E3s (Kikkert, 
Doolman et al. 2004). More evidences also support roles for UBE2J1 and 
UBE2J2 (Lenk, Yu et al. 2002; Arteaga, Wang et al. 2006).
The first mammalian ubiquitin ligases integral to the ER membrane 
shown to function in ERAD were gp78 (Fang, Ferrone et al. 2001) and Hrdl 
(Kikkert, Doolman et al. 2004). In addition, some cytosolic E3s also function 
in ERAD like Parkin (Imai, Soda et al. 2001) and CHIP (Younger, Chen et al. 
2006). Finally, it has to been underscored that the accumulation of ERAD 
substrates may induce the unfolded protein response (UPR), which if 
unresolved will trigger either apoptosis or autophagy (Ding, Ni et al. 2007).
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1.3.2 Monoubiquitylation
Monoubiquitylation is implicated in a plethora of cellular processes 
such as endocytosis of plasma membrane proteins, DNA repair, histone 
activity and transcriptional regulation.
Histones were found to be monoubiquitylated more than 20 years ago 
(Haas, Bright et al. 1988), but only during the past years several functions 
have been identified for histone ubiquitylation. Histones H2A and H2B are 
modified by monoubiquitin or short ubiquitin chains on lysines (Lys) in their 
carboxy-terminal tails. In mammalian cells, ~10% of H2A and ~1% of H2B 
are ubiquitylated but in the budding yeast Saccharomyces cerevisiae, H2B is 
the predominant ubiquitylated histone. Further evidence that is consistent 
with a role for histone ubiquitylation in meiosis comes from the examination 
of mutants that are defective in the Rad6 (E2), which catalyses the 
ubiquitylation of H2A and H2B in yeast. Yeast rad6 mutants, like the H2B 
mutants, cannot sporulate (Prakash 1989) and mouse knockouts lacking a 
Rad6 homologue (HR6B) are specifically defective in spermatogenesis, 
leading to male infertility (Roest, van Klaveren et al. 1996).
In mammalian cells, several ion channels and signal-transducing receptors 
that undergo regulated internalization are ubiquitylated in response to an 
extracellular signal and ubiquitylation regulates their endocytic transport. The 
first clue that monoubiquitin, and not ubiquitin chains, controls these 
processes came from studies on Ste2p, a pheromone G protein-coupled 
receptor in Saccharomyces cerevisiae (Terrell, Shih et al. 1998). More recent 
studies in mammalian cells have shown that chimerae consisting of 
monoubiquitin fused to the cytoplasmic regions of the invariant chain of the 
interleukin-2 receptor a chain or epidermal growth factor receptor (EGFR) 
can be efficiently downregulated by monoubiquitylation. These receptors are 
constitutively internalized from the cell surface and targeted to the late 
endosomal/lysosomal compartment, indicating that a single ubiquitin carries 
both internalization and sorting signals. Monoubiquitin is not only required as
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an internalization signal on endocytic cargo; it might also control the activity 
of the endocytic machinery. EPS 15, a protein that interacts with the Clathrin- 
based endocytic machinery, becomes monoubiquitylated upon stimulation of 
cells with EGF, a ligand that upregulates activity of the endocytic machinery. 
The most important E3 ligases that are known to modify plasma membrane 
proteins are: Cbl and Nedd4. Cbl is a proto-oncoprotein that recognizes and 
ubiquitylates activated, phosphorylated growth factor receptors by binding to 
phospho-tyrosines. It is required to downregulate activated receptors by 
endocytosis and subsequent degradation in the lysosome. Nedd4 binds to and 
ubiquitylates the epithelial sodium channel that undergoes ubiquitin- 
dependent degradation in the lysosome. PPXY motifs in channel subunits are 
required for Nedd4 interaction. The yeast homologue of Nedd4, Rsp5, is 
required for the ubiquitylation and internalization of several proteins.
It is well documented the relationship between monoubiquitylation and 
Fanconi Anemia (FA) in which patients are highly sensitive to DNA cross- 
linking agents such as mitomycin C (Smogorzewska, Matsuoka et al. 2007). 
Eight proteins form the Fanconi anemia complex, a nuclear E3 ubiquitin 
ligase which monoubiquitylates Fanconi anemia group D2 protein (FANCD2) 
and its paralog, Fanconi anemia complementation group I protein (FANCI), 
both of which are involved in the FA DNA repair pathway (Smogorzewska, 
Matsuoka et al. 2007). FANCD2 and FANCI form an “ID complex” that co- 
localizes to chromatin upon DNA damage. Following DNA damage, 
FANCD2 is phosphorylated by the S phase checkpoint kinase, CHK1, which 
triggers DNA damage inducible monoubiquitylation of FANCD2 (Zhi, 
Wilson et al. 2009). FANCI is subsequently monoubiquitylated, DNA 
damage induced foci are formed and additional proteins involved in DNA 
damage response are recruited. Interestingly, FANCD2 and FANCI 
demonstrate a “dual ubiquitin-locking mechanism” where maintenance of 
monoubiquitylation of either protein is dependent on the monoubiquitylation 
status of the other (Smogorzewska, Matsuoka et al. 2007). Thus
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phosphorylation and monoubiquitylation of the ID complex is required for 
recruitment to the damage site on chromatin where it directs the removal of 
damaged DNA and DNA repair (Smogorzewska, Matsuoka et al. 2007). 
Recently, Shereda and co-workers have identified FAN1, a protein with a 
nuclease domain and a ubiquitin-binding domain (UBZ4), which localizes to 
stalled replication forks and is required for mitomycin C resistance (Shereda, 
Machida et al. 2010). They demonstrated that the UBZ4 domain binds 
directly to ubiquitin and is required for proper localization of FAN1 upon 
DNA damage. It was thought that FAN1 is recruited to chromatin by binding 
to monoubiquitylated FANCD2, and its recruitment and nuclease activity are 
required for DNA interstrand crosslinks (ICL) repair.
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1.4 Ubiquitin-like modification
To date, eleven small peptides have been identified as ubiquitin-like 
proteins (UBLs) even though some show very little resemblance to ubiquitin 
(Schwartz and Hochstrasser 2003) (TABLE 1). UBLs attachments principally 
regulate interactions with other macromolecules, such as proteasome- 
substrate binding or recruitment of proteins to chromatin. Different UBL 
systems use related enzymes to attach specific UBLs to proteins (or other 
molecules), and most UBL attachments are transient. Although some of the 
biological functions of these modifications are starting to be deciphered, in 
most cases we have yet to learn how the UBL modification elicits a particular 
change in protein activity. Moreover, the ubiquitin family of protein modifiers 
is thought to derive from a single ancestral conjugation system (Schwartz and 
Hochstrasser 2003). This may raise the question of whether, after their 
multiplication and divergence during evolution, some of the UBL conjugation 
systems retain any functional overlap or cross-regulation.
Attachment of ubiquitin-like proteins (UBLs) to their targets via 
multienzyme cascades constitutes a central mechanism through which protein 
functions are modulated. All UBLs display the common ubiquitin superfold, 
and in general, have their own discrete E1-E2-E3 cascades, and impart 
distinct functions to their targets. As in the ubiquitylation pathway, UBL 
modification is initiated by their dedicated family of mechanistically and 
structurally related El enzymes which are essential for all further conjugation 
(Huang, Hunt et al. 2007). E ls play a critical function in initiating UBL 
conjugation cascades: selecting the correct UBLs for the pathway and 
transferring the UBL to their cognate E2.
Besides the well-studied SUMO (see below), a number of other UBLs 
function in diverse biological pathways. The conjugation of two UBLs -  
interferon stimulated gene 15 (ISG15) and FAT10 - are under the control of 
the interferon system, which responds to viral signals. ISG15 -  the product of
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an interferon inducible gene - is activated by the E l UBA7 and is transferred 
to dozens of targets in a wide range of pathways through a specific E2, 
ubiquitin conjugating enzyme 8 (UBCH8), whose expression is also under 
interferon control (Zhao, Beaudenon et al. 2004; Zhao and Blobel 2005). 
Additional UBLs, including the autophagy related protein 8 (ATG8) and 
ATG12 families, ubiquitin fold modifier 1 (UFM1) and ubiquitin-related 
modifier 1 (URM1) are activated by their own El enzymes (ATG7, UBA5 
and UBA4, respectively). ATG8 and ATG12 are involved in multiple steps in 
autophagy, a process by which cells degrade their cytoplasmic organelles 
through the lysosome. In contrast, URM1 is functionally distinct in that it is 
used in biosynthetic reactions that involve sulfur transfer. Another UBL is 
NEDD8, which is an 81 amino acids ubiquitin-like protein (Liakopoulos, 
Doenges et al. 1998). Neddylation is initiated by a specific E l enzyme, 
NAE1-UBA3 (Gong and Yeh 1999) that first uses ATP to form a NEDD8 
adenylate and then transfers NEDD8 from the adenyl group to a specific 
cysteine (Cys) within NAE forming an "activated" NAE-NEDD8 thioester. 
The activated NEDD8 is then transferred to the active site cysteine in either 
UBE2M or UBE2F, the E2s specific for the NEDD8 pathway. Finally, the 
resulting UBE2~NEDD8 thioester conjugate serves as the direct source of 
NEDD8 to be covalently attached to a cullin’s acceptor lysine (Lys). Recent 
studies suggest that SCCRO (DCN1), a protein that has been shown to 
interact with UBC12 and cullins, acts as a scaffold-type E3 ligase for cullin 
neddylation (Kurz, Chou et al. 2008). NEDD8 is then removed from the 
cullins by the isopeptidase activity of the metalloprotease CSN5/JAB1 
subunit of the COP9 signalosome (Wei 2009). The modification of ubiquitin 
E3s by UBL is also involved in cross-regulation pathway. For instance, both 
SUMO and ubiquitin can modify the same residues of MEK1 and PCNA. 
SUMOylation can protect a protein from degradation by preventing ubiquitin 
ligation (Muller, Hoege et al. 2001) or it can prevent some other effect of
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ubiquitin ligation, such as the stimulation of DNA repair in the case of PCNA 
(Hoege, Pfander et al. 2002).
1. SUMOylation pathway
The ubiquitin-like protein SUMO is distantly related to ubiquitin (16- 
18% identity) and was first identified in mammals, where it was found to be 
covalently linked to the GTPase activating protein RanGAPl (Mahajan, 
Delphin et al. 1997). The E l activating and E2 conjugating enzymes involved 
in SUMOylation are highly related to the E l and E2 enzymes that participate 
in ubiquitylation. In contrast to the ubiquitin system where dozens of E2 
enzymes have been identified, Ubc9 is the only known SUMO E2 
conjugating enzyme. All SUMO isoforms are conjugated via a conserved 
enzymatic cascade that resembles that of ubiquitin conjugation (Figure 5). 
SUMO is first activated by formation of a thioester bond between its C- 
terminal glycine (Gly) and the catalytic cysteine (Cys) of the heterodimeric 
El activating enzyme (Aosl/Uba2, also named SAE1/SAE2). This step 
requires ATP hydrolysis. SUMO is then transferred to the catalytic Cys of the 
single E2 conjugating enzyme Ubc9. The last step consists in the transfer of 
SUMO from the E2 to the 8-amino group of a lysine (Lys) side chain on the 
substrate, which results in isopeptide bond formation. For this, Ubc9 needs to 
recognize a specific acceptor site in the target. Many -  but not all -  targets 
contain the so-called SUMO consensus motif, tpKxE, where W  is a large 
hydrophobic residue and K the acceptor lysine. The interaction between Ubc9 
and most targets is not stable enough for efficient transfer, and therefore 
requires additional proteins, the so-called E3 ligases. Currently known ligases 
include PI AS (Protein inhibitor of activated ST AT) proteins (Shuai and Liu
2005) , the nucleoporin RanBP2/Nup358 (Pichler, Gast et al. 2002) and the 
polycomb protein Pc2 (Kagey, Melhuish et al. 2003). Notably, the different 
SUMO E3 ligases identified to date have distinct subcellular localizations:
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RanBP2 is associated with the nuclear pore complex, the PIAS proteins are 
found in the nucleoplasm and nuclear bodies, and Pc2 is found in a 
subnuclear structure called Polycomb body (Kagey, Melhuish et al. 2003). 
Localization of the SUMO E3 ligases is likely to contribute to functional 
specificity in vivo. However, the list of SUMO E3 ligases is growing as 
additional proteins with SUMO E3 ligase activity have been recently 
identified. For example, histone deacetylase 4 (HDAC4) can promote the 
SUMOylation of MEF2, independent of its deacetylase activity (Zhao and 
Blobel 2005). The human topoisomerase I- and p53-binding protein Topors 
can function as both a ubiquitin and a SUMO E3 ligase for p53 (Weger, 
Hammer et al. 2003). SUMO conjugation is reversible, and the SUMO- 
specific protease (SENP) family is responsible for rapid removal of SUMO 
from SUMOylated protein substrates (Hay 2007). Whether other types of 
SUMO isopeptidases exist is still not clear. All SENPs share a conserved 
catalytic domain but have distinct N-terminal extensions, which might be 
responsible for their different intracellular localisations.
Since the identification of the first SUMO-modified protein, RanGAP, 
in 1996 (Matunis, Coutavas et al. 1996), a large number of proteins have been 
shown to be post-translationally modified by SUMO and new substrates of 
SUMO-modification continue to be identified at a rapid pace. Many of the 
known targets of SUMOylation are nuclear proteins with important roles in 
regulating transcription, chromatin structure, and DNA repair. Furthermore, 
the nuclear targets of many signalling pathways including TGF|3, Wnt, and 
cytokines are post-translationally modified by SUMO. It is interesting to note 
that some of the proteins that have been found to be modified by SUMO are 
also post-traslationally modified by ubiquitin, often with different 
consequences (Hunter and Sun 2008). In some cases, SUMO modification has 
been shown to compete with ubiquitylation or acetylation for common lysine 
residues. In most cases SUMO modification is likely to regulate protein- 
protein interactions.
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TABLE 1
UBL UbiquitinSequence
Homology
(% )
E l and E2 
enzymes
Substrates Functions
ISG15 (UCRP) 
(2 ubiquitins)
29,27
El: UBE1L; 
E2: UBCH8
PLC *h,JA K l,STA Tl, 
ERK1/2, serpin 2a
Regulator of 
IFN-related 
immune 
response
FUB1
(MNSFB) 37
NA TCR- Cf-like protein, Bcl-G
Negative 
regulator of 
leukocyte 
activation and 
proliferation
NEDD8
(Rubl) 58
El: APPBP1- 
UBA3;
E2: UBC12;
cullins, p53, Mdm2, 
synphilin-1
Positive 
regulator of 
ubiquitin E3s; 
proteasomal 
degradation
FAT 10 (2 
ubiquitins) 29,36
NA MAD2
Cell cycle
checkpoint for
spindle
assembly;
proteasomal
degradation
SUMO 1-3 16-18
El: SAE1/2; 
E2: UBC9
c-Jun, I tZB <Tr, p53, Mdm2, 
SOD-1, NEMO, PML, 
Sam68, RanGAPl, etc.
Transcription 
regulation, cell 
cycle
progression
Atg 8 10
El:Apg7; 
E2: Apg3;
Phosphatidylethanolamine Autophagy,
Atg 12 17
El: Apg7; 
E2: ApglO
Atg 5 Autophagy,
Urml 12
El: Uba4
Ahpl
Potential role in 
oxidative stress 
response
UBL5 (Hubl) 25 NA CLK4, Snu66, Sphl, Hbtl
Pre-mRNA
splicing,
appetite
regulation
Ufml 16
El: Uba5; 
E2: Ufcl
NA
Potential role in 
endoplasmic 
stress response
Ubiquitin-like proteins for which there is experimental evidence for ligation to other molecules. The 
ubiquitin superfamily consists of numerous proteins that display structural similarity to ubiquitin and 
are involved in a range of biological activities.
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Figure 5
SUMO hydrolases j,
SUMO
isopeptidases
ATP
Uba2 )cf73-S ~G
E1 activating 
enzyme
+ E3 ligases
Ubc9)CM-S~G
K.
(Bossis and Melchior 2006)
target
JL
target
E2 conjugating 
enzyme
The SUMOylation pathway. SUMO is first activated in an ATP-dependent process by forming a 
thioester bond with the catalytic Cys of the El-activating enzyme, which is a heterodimer consisting of 
two proteins SAE1 and SAE2 (also known as Aosl and Uba2, respectively). SUMO is transferred to 
the catalytic Cys of the E2-conjugating enzyme Ubc9, which directly binds to substrates. Subsequently, 
SUMO is conjugated to the protein substrate by forming an isopeptide bond between SUMO and the e- 
amino group of a lysine side chain on the substrate. SUMO conjugation is reversible, and the SUMO- 
specific protease (SENP) family is responsible for rapid removal of SUMO from SUMOylated protein 
substrates.
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1.5 The TRIM protein family
The proteins that belong to the tripartite motif (TRIM) family (also 
known as the RBCC family) are defined by the presence of a RING (R) 
domain, one or two B-box domains and a coiled-coil (CC) region (Borden 
2000; Reymond, Meroni et al. 2001) (see below). The RING domain is 
present in hundreds of other proteins, while the zinc-binding B-box domain is 
a critical determinant of the tripartite motif family. This motif is invariably 
present at the N-terminal portion of these proteins, while their C-terminus 
presents various domains.
The TRIM proteins self-associate, mainly through their coiled-coil 
region, and homo-interaction results in the formation of large protein 
complexes (Reymond, Meroni et al. 2001). 68 proteins belong to this family 
and are involved in many cellular processes such as apoptosis, cell cycle 
regulation, and viral response (Sardiello, Cairo et al. 2008).
Many TRIM proteins have been characterized for their subcellular 
localization and shown to be associated with specific compartments, such as 
nuclear bodies (PML/TRIM19, TIF1/TRIM24 and RFP/ TRIM27) or the 
microtubules (MID1/TRIM18 and MID2/TRIM1) (Dyck, Maul et al. 1994; 
Le Douarin, Zechel et al. 1995; Cao, Duprez et al. 1998; Buchner, Montini et 
al. 1999; Cainarca, Messali et al. 1999). The great majority of TRIM proteins 
localize to discrete cytoplasmic or nuclear compartments sometimes 
associated with a diffusely stained background (Figure 6) (Reymond, Meroni 
et al. 2001). In the case of cytoplasmic TRIM proteins, the cellular 
compartments are associated with filaments, or assume a cytoplasmic ribbon­
like structure (Reymond, Meroni et al. 2001). Other TRIM proteins are 
concentrated in cytoplasmic bodies of variable size, occasionally located 
around the nucleus (Reymond, Meroni et al. 2001). Nuclear TRIM proteins 
localize to structures best described as nuclear body or nuclear sticks. In 
particular, PML is required for NB formation and is necessary for the
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recruitment of other components into the NBs. In fact, deletion of PML 
results in a lack of formation of NBs (Melnick and Licht 1999).
Genetic alteration in genes encoding TRIM proteins can result in 
human diseases: TRIM 18 is mutated in X-linked Opitz/GBBB syndrome 
(Quaderi, Schweiger et al. 1997); TRIM19/PML, and TRIM27/RFP, acquire 
oncogenic activity when fused to RARa and RET respectively (Takahashi 
1988); EFP/TRIM25 is implicated in tumour progression and growth (Urano, 
Saito et al. 2002); TRIM54 is upregulated in a model of muscle atrophy 
(Bodine, Latres et al. 2001); TRIM32 is associated with both skin 
carcinogenesis and Limb-Girdle Muscular Dystrophy type 2H (LGMD2H) 
(Frosk, Weiler et al. 2002); TRIM37/MUL is involved in the pathogenesis of 
Mulibrey nanism, a syndromic form that affects muscle, liver, brain and eye 
(Avela, Lipsanen-Nyman et al. 2000); TRIM20/Pyrin/Marenostrin is mutated 
in Familial Mediterranean Fever, an inflammatory disease (1997; Chae, 
Komarow et al. 2003). Recently TRIM protein antiviral activity is emerging 
(Nisole, Stoye et al. 2005; Ozato, Shin et al. 2008). TRIM5a was shown to 
inhibit the replication of lentiviruses including HIV-1 (Stremlau, Owens et al. 
2004); TRIM1 and TRIM22 interfere with the replication of N-tropic murine 
leukemia virus (N-LMV) and human immunodeficiency virus (HIV-1), 
respectively (Ozato, Shin et al. 2008). TRIM30a negatively regulates Toll­
like receptor (TLR)-mediated NF-kB activation (Shi, Deng et al. 2008). 
TRIM21/Ro52 is a target autoantigen in several systemic autoimmune 
diseases, including Systemic lupus erythematosus (SLE) and Sjogren’s 
syndrome (Hennig, Bresell et al. 2008).
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Figure 6
TRIM proteins homomultimerize and associate with specific subcellular structures. Subcellular 
localization of TRIM29 (A), TRIM4 (B), TRIM2 (C), TRIM5 (D), TRIM8 (E), TRIM13 (F), TRIM28 
(G) and TRIM9 (H) (Reymond et al., 2001).
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1.5.1 TRIM domain structure
1 . The Tripartite motif
As already discussed in the previous paragraph, the RING motif is 
defined by a regular arrangement of cysteine (Cys) and histidine (His) 
residues that coordinate two atoms of zinc (Figure 7). There are two main 
RING subtype, H2 and C2. Of the two RING subtypes, the C2, which is 
characterized by a Cys residue in the fifth coordination site, is found in the 
TRIM family (Meroni and Diez-Roux 2005). With few exceptions, the RING 
domain is typically found within 10-20 amino acids of the TRIM protein first 
methionine (Torok and Etkin 2001).
The B-box domain is another zinc-binding motif that occurs in two 
flavours, B-boxl and B-box2, which present a similar but distinct pattern of 
cysteine and histidine residues (Figure 7) (Reymond, Meroni et al. 2001). 
The B-box domains usually adopt a P(3a conformation similar to RING 
domain’s one. B-boxl and B-box2 diverge in the second potential 
coordination residue, which is a Cys in B-boxl and a His in B-box2. In 
addition, the B1 and B2 domains have different lengths and, when found 
together, B-box type 1 always precedes type 2. In TRIM proteins, B-box 
domain usually mediates the interaction with TRIM’S interactor protein.
A coiled-coil region always follows the B-box2 in the entire set of 
TRIM proteins. This region is approximately 100-residue-long, and it is 
frequently spilt into two separate coiled-coil motifs. The coiled-coil region in 
the TRIM family is mainly involved in homo-interaction and in promoting the 
formation of high molecular weight complexes. Disruption of the TRIM 
coiled-coil region is associated with diffuse localization (Reymond, Meroni et 
al. 2001); in contrast, independent deletions of RING or B-boxl and B-box2 
induce relocalization of the mutant protein to aberrant cellular structures 
(Reymond, Meroni et al. 2001).
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The striking structural feature of this family is the rigid conserved 
pattern, combination and order of the domains, which strongly suggests that 
this minimal structure was selectively maintained to carry out a specialized 
basic function common to all tripartite motif proteins. The order of the 
domains within the tripartite motif (RING, B-boxl, B-box2, and coiled-coil) 
is maintained from the N-terminus to the C-terminus, if one domain is absent, 
the order of the remaining ones is conserved. These observations suggest that 
the tripartite motif is an integrated functional structure, rather than a 
collection of separate modules.
2. The C-terminal domain
While the tripartite motif, and especially the B-box domain, is 
restricted to this protein family, the C-terminal domains found in the TRIM 
proteins is also present in otherwise unrelated proteins. A number of TRIM 
proteins do not possess a defined C-terminal domain; in this case, either their 
coding region is limited to the tripartite motif or the C-terminal portion is not 
similar to any known domains or proteins. Two thirds of the TRIM members 
have a B30.2 or PRY-SPRY domain, also known as RFP-like domain having 
been first identified in TRIM27/RFP (Meroni and Diez-Roux 2005) (Figure 
8). It is a 170-residue long domain composed of three blocks named after the 
more conserved amino acid stretches, LPD (also known as PRY), WEVE and 
LDYE (also known as SPRY domain) motifs (Henry, Mather et al. 1998). 
Recently RFP region has been associated to TRIM22 formation of distinct 
nuclear bodies (Sivaramakrishnan, Sun et al. 2009) and TRIM5 protein 
retroviral restriction (Stremlau, Owens et al. 2004). Interestingly, TRIM20 
mutations in RFP domain have been strictly associated to Familial 
Mediterranean Fever (FMF)(Chae, Komarow et al. 2003). A less frequent C- 
terminal domain within the TRIM family is the NHL domain. It consists of 2- 
6 repeats, usually 5 or 6 in the TRIM proteins, of an approximately 40-residue 
sequence that resembles the WD repeat and that assembles to form multiblade
propeller structure (Slack and Ruvkun 1998). The TRIM proteins that contain 
a PHD associated to a BROMO domain represent a more homogeneous 
subfamily composed of four members, the TIF1 proteins, which share high 
homology along the entire length of their sequence and participate in similar 
cellular processes (Moosmann, Georgiev et al. 1996).
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Figure 7
RING consensus
C-X2 -C-Xjj.j6 -C-x-H-X2 -C-X2 -C-X7 .7 4 .C-X2 - [CD]
B-boxl consensus
C-x2 -C-x7 _1 2 -C-x2 -C-x4 -C-x2- [CH]-X3 .4 -H-X4 .9 -H 
B-box2 consensus
C-x2-H-x7 9-C-x2- [CDHE]-x4-C-x2-C-x3.6-H-x2 4- [CH]
RING, B-boxl and B-box2 consensus sequences. Consensus sequences for the RING, B-boxl and B- 
box2 domains within the tripartite motif RING consensus: in blue are the cysteines involved in the first 
zinc atom coordination while the red residues are involved in the second metal binding. B-box2 
consensus: in blue are the residues involved in zinc coordination.
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Figure 8
TRIM 1 R- -B 2-C C -F N 3-
TRIM 2 R-B2-CC-IGFLM N-NHL(6)
TRIM 3 R-B2-CC-IGFLM N-NHL(6)
TRIM 4 R-B2-CC-
TRIM 5 R-B2-CC-
TRIM 6 R -B2-CC-
TRIM 7 R-B2-CC
TRIM 8 -B 2-C C -nd
TRIM 9 R- -B 2-C C -F N 3-
TRIM 10 R-B2-CC-
TRIM 11 R -B2-CC-
TRIM 13 R-B2-CC-TM
TRIM 14 B 2-cc-
TRIM 15 R -B2-CC-
TRIM 16 -B 2-C C -
TRIM 17 R-B2-CC-
TRIM 18 R- -B 2-C C -F N 3- j
TRIM 19 R- -B 2 -cc -n d
TRIM 2 0 PAAD-B2-CC-
TRIM 21 R -B2-CC-
TRIM 2 2 R-B2-CC-
TRIM 2 3 R-B2-CC-ARF
TRIM 2 4 R- -B2-CC-PHD-BROM O
TRIM 2 5 R- -B 2-C C -
TRIM 2 6 R-B2-CC-
TRIM 2 7 R-B2-CC-
TRIM 2 8 R- -B2-CC-PHD-BROM O
TRIM 2 9 -B 2-C C -nd
TRIM 31 R-B 2-C C -nd
TRIM 32 R- -CC-NH L(5)
TRIM 3 3 R- -B2-CC-PHD-BROM O
TRIM 3 4 R-B2-CC-
TRIM 3 5 R-B2-CC-
TRIM 3 6 R- -B2-CC-FINI3-
TRIM 3 7 R-B2-CC-MATH
TRIM 3 8 R-B2-C C -
TRIM 3 9 R-B2-C C -
TRIM 4 0 R-B2-CC
TRIM 4 1 R-B2-CC-
TRIM 4 2 R- -B2-CC-FN3
TRIM 4 3 R-B2-CC-
TRIM 4 4 61-B 2-C C
TRIM 4 5 R- -B 2-C C -IG  FLMN
TRIM 4 6 R -B 1-B 2-C C -FN 3
TRIM 4 7 R-B1-B2-CC-
TRIM 4 8 R-B2-CC
TRIM 4 9 R-B2-CC-
TRIM 5 0 R-B2-CC-
TRIM 73 R-B2-CC
TRIM 7 4 R-B2-CC
TRIM 5 2 R-B2
TRIM 5 4 R-B2-CC-nd
TRIM 55 R-B2-C C -nd
TRIM 5 6 R-E :-B 2-C C -nd
TRIM 58 R-B2-CC-
TRIM 5 9 R-B2-CC-TM
TRIM 6 0 R-B2-CC-
TRIM 61 R-B2-CC-
TRIM 6 2 R-B2-CC-
TRIM 6 3 R-B2-C C -nd
TRIM 6 4 R-B2-CC-
TRIM 6 5 R-B2-CC-
TRIM 6 6 -B2-CC-RPT
TRIM 6 7 R-E J -B 2-C C -F N 3-
TRIM 6 8 R-B2-CC-
A schematic representation of the TRIM proteins identified. Colour coding is as fellows: red R, RING 
domain; light blue B l, B-box typel domain; dark blue B2, B-box type 2 domain; green CC, coiled-coil 
region; yellow PRY/SPRY, RFP -like region; black PHD-BROMO domain.
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1.5.2 TRIM proteins as E3 Ubiquitin Ligases
As reported above, RING finger proteins are the largest class of Ubiquitin 
Ligases. The broad use of the RING domain in ubiquitylation may suggest 
that the TRIM family, characterized by the presence of a RING finger within 
the tripartite motif, represents a subclass of single protein RING finger E3s. 
This hypothesis is supported by recent experimental data, which demonstrate 
the E3 ubiquitin ligase activity of some family members.
Efp/TRIM25, an estrogen-responsive gene, has been shown to 
selectively control the protein level of 14-3-3a , a cell cycle regulator (Urano, 
Saito et al. 2002). This control is exerted, in a proteasome-dependent manner, 
through direct binding between Efp and both substrate, 14-3-3a, and an E2 
Conjugating Enzyme, UbcH8 (Urano, Saito et al. 2002). As expected, the E2 
enzyme binds the RING domain of Efp while the B-boxes and the coiled-coil 
region mediate substrate interaction. Midl/TRIM18, the protein altered in 
Opitz syndrome, controls the level of the catalytic subunit of microtubular 
phosphatase 2A (PP2Ac) (Trockenbacher, Suckow et al. 2001). In this case, 
TRIM 18 binds directly to a subunit of the PP2A complex, alpha 4, through 
the B-box 1 region (Liu, Prickett et al. 2001). TRIM8/GERP regulates SOCS- 
1 (suppressor of cytokine signalling 1) activity by controlling its degradation 
through direct binding via its B-box and coiled-coil region (Toniato, Chen et 
al. 2002). Along the same line, TRIM 11 binds and regulates the level of 
humanin, a neuroprotective 24-residue-peptide, via the coiled-coil SPRY 
domain (Niikura, Hashimoto et al. 2003) and it is also implicated in the 
degradation of ARC 105 (Ishikawa, Tachikawa et al. 2006). Recent data 
suggest that TRIM32 interacts with and promotes the ubiquitylation and 
degradation of PI AS family members (Albor, El-Hizawi et al. 2006), Abl- 
interactor 2 (Kano, Miyajima et al. 2008) and dysbindin (Locke, Tinsley et al.
2009). The importance of RING domain is due not only to its capacity to 
recruit the E2, but also to its catalytic role. The preference for specific E2s 
has been demonstrated for some of the above-mentioned TRIM E3s: UbcH8
but not UbcH7 for Efp (Urano, Saito et al. 2002), UbcH5B but not Ubc8 and 
Ubcl3 for TRIM56 (Xu, Yang et al. 2003), UbcH5 and UbcH6 for TRIM32 
(Albor, El-Hizawi et al. 2006). Moreover, experimental evidence confirmed 
that the RING domain is involved in mediating their E3 activity. The central 
role of this domain is also demonstrated by the plethora of TRIM proteins 
whose cellular activity is compromised in RING domain mutants.
While the tripartite motif might serve as the module to bring the 
ubiquitin-E2, bound to the RING domain, in close proximity to the substrate, 
bound to the B-box/coiled-coil region, the role of C-terminal domain in the 
E3 activity is still unclear. These domains are also present in non-TRIM 
proteins and, in some cases, have been shown to interact with proteins 
involved in the ubiquitylation process. In particular, the B30.2 domain has 
been reported to interact with proteasome subunits and ubiquitin itself 
(Suzumori, Burns et al. 2003). It is interesting to notice that another TRIM C- 
terminal domain, PHD, has been also associated to ubiquitylation (Lu, Xu et 
al. 2002).
The TRIM-defined compartments contain many other proteins that 
either interact or simple co-localize with the TRIM proteins. It has been 
observed that, in addition to homo-interaction, some TRIM proteins hetero- 
interact or co-localize with each other, e.g. TRIM1-TRIM18, TRIM6-TRIM8, 
TRIM1-TRIM3. It is also noteworthy that many of the non-TRIM partners are 
proteins involved in ubiquitylation or contain domains present in proteins 
belonging to this pathway, often other RING-containing proteins. This point 
is important because E3 enzymes can in turn be regulated through 
ubiquitylation and be substrates of other E3s or of themselves. Some TRIM 
proteins have been observed to mediate their auto-ubiquitylation in vitro and 
hetero-interacting TRIM proteins might regulate their ubiquitylation. In 
addition, TRIM proteins may play a role in the “non-proteolytic” function of 
ubiquitin and ubiquitin-like modification. TRIM19/PML is the principal 
component and organizer of nuclear bodies (NB) to which a conspicuous
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number of proteins localize. PML is associated to various cellular process, 
apoptosis, senescence and cellular viral response through epistatic 
transcriptional regulation and interactions with many partners such as p53 and 
Rb (Jensen, Shiels et al. 2001 {Pearson, 2001 #652; Pearson and Pelicci 
2001). A component of NB is SUMO-1, one of the first UBL proteins 
discovered (see paragraph 1.2) and PML is modified by SUMO. A subgroup 
of TRIM protein, known as Transcription Intermediary Factors 1 (TIF1), has 
been implicated in epigenetic mechanisms of transcriptional regulation 
involving histone modifiers and heterochromatin-binding proteins (Le Douarin, 
Zechel et al. 1995). These TRIM proteins may be involved in regulating 
transcription through a basic mechanism that implicates ubiquitin-dependent 
transcriptional processes.
Since mutations in TRIM genes result in several pathological 
conditions, these events could be linked to their E3 Ubiquitin Ligase activity. 
Two interesting examples in which E3 activity and physiological substrate 
have been identified are MID 1/TRIM 18 and TRIM32. The first is responsible 
for a rare genetic syndrome, X-linked Opitz Syndrome (OS), a congenital 
human disease shown to result from mutations in the MIDI gene and that 
affects midline development (Cainarca, Messali et al. 1999). OS-causing 
mutations are scattered along the entire length of the MIDI gene and affect 
the ability of its protein product to bind microtubules (Schweiger, Foerster et 
al. 1999). Moreover, MIDI B-box domain region binds Alpha4, a regulatory 
subunit of the PP2A-type phosphatases including the principal cellular 
phosphatase, protein phosphate 2A (PP2A) (Chen, Peterson et al. 1998). The 
implication of MIDI in the Alpha-4-mediated regulation of phosphatase 
activity may provide valuable clues as to the pathophysiological 
consequences of MIDI mutations that underlie Opitz syndrome (Short, 
Hopwood et al. 2002). In the case of TRIM32, within its fourth NHL repeat, a 
mutation of an evolutionarily conserved aspartic acid to asparagines is linked 
to the development of Limb-Girdle Muscular Dystrophy type 2H (LGMD2H),
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an autosomal recessive myopathy (Frosk, Weiler et al. 2002). TRIM32 is 
primary expressed in skeletal muscle and its level is significantly elevated in 
muscle undergoing remodelling due to changes in weight bearing. 
Furthermore, expression of TRIM32 is induced in myogenic differentiation 
and it associates with skeletal muscle thick filaments, interacting directly with 
the head and neck region of myosin (Kudryashova, Kudryashov et al. 2005). 
TRIM32 ubiquitylates actin, acting as an E3 Ubiquitin Ligase, and associates 
with myofibrils suggesting its likely participation in myofibrillar protein 
turnover, especially during muscle adaptation (Kudryashova, Kudryashov et 
al. 2005).
As expected for their role in the ubiquitin pathway, TRIM proteins are 
involved in several physiological and pathological conditions. Studies on the 
down-stream target proteins will provide further insight into the molecular 
mechanism underlying human disease associated to this family.
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CHAPTER 2: AIM OF THE PROJECT
The TRIM family represents a sub-class of RING finger proteins that 
are characterized by the presence of the TRIpartite Motif, which consists of a 
RING domain, one or two B-box motifs and a coiled-coil region (Reymond, 
Meroni et al. 2001). In humans, the TRIM family has 6 8  members and they 
are involved in many cellular processes such as apoptosis, cell cycle 
regulation, and innate cellular response to retroviral infections. The presence 
of the RING domain and its strong association to ubiquitylation suggest a role 
for this protein family in the ubiquitylation process as E3 ubiquitin ligases.
The E3 enzyme catalyzes the most important step in the ubiquitylation 
cascade: the interaction with the ubiquitin charged E2 and the substrate. 
TRIM proteins represent the largest subfamily of the RING domain putative 
E3 ligases. Indeed, previous studies have demonstrated the E3 function for 
some TRIM family members, e.g. TRIM23/ARD1, TRIM11, TRIM 18/Mid 1, 
TRIM21/Ro52, TRIM25/Efp, and TRIM32 (Meroni and Diez-Roux 2005).
During the ubiquitylation process, target protein specificity is provided 
by the E3, whereas the E2 and E3 combination determines the topology and 
length of the ubiquitin chains that will determine the fate of the substrate 
(degradation of misfolded protein, cell signalling, transcription, regulation of 
cell cycle, etc). However, to date very little is known about the specificity of 
human E2/E3 RING interactions and how this is achieved and regulated. In 
the case of the TRIM proteins, even when the E3 activity is assessed, little is 
known about the specific UBE2 partner usage and if TRIM-UBE2 binding 
correlates with different TRIM RING sequence.
The aim of my thesis is to provide a well-defined analysis of the 
interactions between TRIM family members and E2 enzymes assessing their 
E3 activity. These data could give an important indication to understand how 
E2-TRIM complexes might build different types of ubiquitin chains that will 
determine substrate fate.
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Moreover, the involvement of some TRIM family members in specific UBLs 
(i.e. TRIM25-ISGylation and TRIM19-SUMOylation) raises the question of 
whether all TRIM family members might act as UBL E3 ligases. In particular 
I will investigate TRIM proteins specific involvement in SUMOylation 
pathway whose known targets are nuclear proteins with important roles in 
regulating transcription, chromatin structure and DNA repair.
These results could strongly indicate a role of the TRIM proteins as E3 
Ubiquitin/Ubiquitin Like Ligase suggesting a possible usage of TRIM family 
as model to study the cross-talk between ubiquitylation and SUMOylation.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Cloning strategy
The full-length cDNAs of twenty-six Ubiquitin Conjugating Enzymes 
E2 (UBE2) (TABLE 2) were cloned into pEG202 and pJG4-5 vectors (see 
paragraph 3.2), which are designed for DNA expression in yeast, and into 
pCDNA3-HA and pCDNA3-MycGFP vectors (see paragraph 3.3), which are 
designed for protein expression in mammalian cells; the full-length cDNAs of 
six TRIM proteins were cloned into pMal c2x vector (see paragraph 3.4), 
which is designed for protein expression in E. coli cells.
3.1.1 RNA extraction
Total RNA for each time point was extracted from Hela and HEK 293 
cells with the RNeasy mini Kit (Qiagen). Total RNA was quantified by 
spectrophotometer analysis, diluted to lOOng/pl final concentration, and 
checked by UV detection after running 4pi of each sample with lp l of 5x 
RNA loading buffer (10ml solution: 80pl of 500mM EDTA pH 8 , 720pl of 
37% formaldehyde, 2ml glycerol, 3084pl formamide, 20mM 3-[N- 
morpholino] propanesulfonic acid (MOPS), 5mM sodium acetate, InM 
EDTA, and some bromophenol blue powder, in 10ml final volume of RNAse- 
free water) on a formaldehyde gel (1.2g agarose, 20mM 3-jN- 
morpholino ^propanesulfonic acid (MOPS), 5mM sodium acetate, and InM 
EDTA in 100ml final volume of RNAse-free water, and brought at pH 7.0 
with NaOH) run in a formaldehyde gel running buffer (20ml of 37% 
formaldehyde, 20mM 3-<jN-morpholino (-propanesulfonic acid (MOPS), 5mM 
sodium acetate).
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cDNA was prepared using 1|ig of total RNA, 200pmol random 
hexamers (Invitrogen) and Omniscript reverse transcriptase (Qiagen) in 30 [xl 
final volume according to manufacturer’s instructions
3.1.2 Production of insert DNA fragments
To clone all genes, Polymerase Chain Reaction (PCR) was performed 
using primers with restriction site-containing tails; usually, the forward 
primer carries either EcoRI or BamHI sites upstream of the ATG start codon, 
which keeps the cDNA in frame with the different tag sequences, and an Xhol 
site downstream of the stop codon. PCR was performed in a volume of 50pl 
samples, using lOOng of cDNA obtained from RNA as described above, 
500nM forward and reverse primers, 5pi of 10X Vent DNA Polymerase 
buffer, 0.2mM dNTPs and 0.5pi (1U) of the high fidelity Vent DNA 
Polymerase (New England Biolabs). The amplification reaction was carried 
out as follows:
• lm inat95°C
• 1 min at 95°C
• 30 sec at 56°C
• 4 min at 75°C
• Steps 2 to 4 are repeated 30 times
• 1 cycle: 10 min at 75°C
In order to check the PCR reaction, 5pi of each sample were loaded on a 
1% agarose gel. Positive samples were subjected to protein extraction by 
adding 1 volume (Vol) of phenol/clorophorm, and centrifuging 1 min at 
14,000 in a bench centrifuge at room temperature (RT). The upper phase was 
collected and DNA was precipitated in 2.5Vol 100% ethanol and 1/10 Vol of
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3M Sodium Acetate pH 4.8. After centrifuging 5min at 14,000 rpm at RT, the 
pellet was washed with lOOpl of 70% ethanol and let dry at RT.
3.1.3 DNA restriction
In order to restrict the fragment tails at the EcoRI and Xhol sites or 
BamHI and Xhol sites, the amplified DNA was incubated as follows: 10-15pi 
of DNA, 3pi of 10X EcoRI or BamHI buffer, which are both compatible also 
for the Xhol restriction enzyme, lp l of EcoRI or BamHI and lp l of Xhol 
restriction enzymes (New England Biolabs), and distilled water to a final 
volume of 30pl. The samples were incubated at 37°C for 2 hrs. The samples 
were loaded on a 1% agarose gel and the DNA bands corresponding to the 
expected size were cut from the gel with a razor blade and extracted using the 
Qiaex extraction kit (Qiagen), according to the manufacturer’s protocol, and 
resuspended in 25pl of IX TE buffer (lOmM Tris-Cl, pH7.5, ImM EDTA). 
Extraction efficiency was determined by loading 5pi on an agarose gel. 
Parallel to this, the pCDNA3-HA, pCDNA3-MycGFP, pEG202, pJG4-5 and 
pMal c2x vectors were restricted with either EcoRI-XhoI or BamHI-XhoI 
restriction enzymes, purified by gel extraction as reported above and 
quantified on a gel.
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3.1.4 DNA ligation
After diluting insert and vector DNA at the final concentration of 
approximately lOOng/pl, the ligation reactions were carried out in final 20pi 
sample volume, adding 2pl 10X ligation buffer, lp l vector DNA, 3-10pl 
insert DNA and 0.5pi T4 DNA Ligase (New England Biolabs), and incubated 
over night at 16°C. lOpl of each reaction was used to transform competent 
DH5a  bacterial cells.
3.1.5 DNA transformation
In order to introduce the constructs into the bacterial host cells, 50pi of 
chemical competent DH5a E. coli cells, with an efficiency of at least 106  
colonies/pg DNA, were incubated for 20 min on ice with 10pi of ligation 
samples, followed by 2 min thermal shock at 42°C; the cells were incubated 
for 5 min on ice and then 1 ml LB was added and cells were incubated 1 hr at 
37°C in a water bath, centrifuged 5 min at 4,500rpm, resuspended in 20pl LB 
and plated on 100mm diameter B-agar Petri dishes containing lOOpg/mg 
ampicillin, which allows the selection of the transformed colonies, as the used 
vectors confer resistance to this antibiotic.
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3.1.6 Purification of plasmid DNA
Plates were incubated over night (o.n.) at 37°C and the colonies were 
picked and grown o.n. at 37°C in liquid LB medium and ampicillin. Plasmid 
DNA preparations were performed using the Qiagen Mini preparation kits, 
according to the manufacturer’ instructions, which provided small amounts of 
purified DNA. After plasmid DNA purification, the constructs were analyzed 
by restriction with either EcoRI-XhoI or BamHI-XhoI enzymes. DNA from 
positive clones was prepared on a larger scale using Qiagen Midi preparation 
kits, according to the manufacturer’s instructions. Correct constructs were 
analyzed by sequencing (service provided by PRIMM).
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3.2 Interaction Mating
The Interaction Mating is a two-hybrid system used to detect 
interactions between known proteins. In the Interaction Mating assay two 
proteins are expressed in yeast: one (the “bait”) contains a DNA-binding 
moiety (see pEG202 vector); the other (“activation tagged” or “prey”) 
contains a trascription activation domain (see pJG 4-5 vector). If the two 
proteins interact, the complex activates trascription of a reporter gene that 
contains a binding site for the DNA-binding domain of the bait. The 
Interaction Mating uses Escherichia coli LexA repressor as the DNA-binding 
moiety and two different reporter genes: LEU2 and LacZ, each of which 
contains upstream LexA operators (see 3.2.1 paragraph).
The Interaction Mating technique relies on the fact that haploid yeast 
have two different mating type: MATa (EGY42 strain) and MATa (EGY48 
strain), which fuse to form diploids (for details see paragraph 4.1.1). Whereas 
the yeast EGY48 strain has an integrated LEU2 reporter gene with its 
upstream regulatory region replaced by LexA operators (see paragraph 4.1.1), 
the yeast EGY42 strain contains a LexAop-lacZ reporter that resides on a 
third plasmid: pSH 18-34 (Figure 9).
pSH 18-34 contains the URA3 gene and the GAL1, transcription start, 
and a small part of the GAL1 coding sequence fused to lacZ. Reporters for 
measuring activation are derived from pLRlA l, in which the GAL1 upstream 
activation sequences (UASG) have been deleted. Various numbers and types 
of LexA operators have been inserted in place of UASG to create lacZ 
reporters with different sensitivities. In particular, pSH 18-34 contains four of 
these colEl operators and so it is more sensitive than the other ones to 
activation by LexA fusions and activation-tagged proteins that interact with 
them (Finley and Brent 1994).
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Figure 9
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A schematic representation of pSH18-34. pSH18-34 contains a yeast origin of replication (2pm ori), the 
yeast selectable marker gene (URA3), and the GAL1 TATA, transcription start, and a small part of 
GAL1 coding sequences fused to LacZ. It also contains an E.coli origin of replication (pBR322ori) and 
the ampicillin resistance gene (AmpR).
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3.2.1 Cloning the Ubiquitin Conjugating Enzyme cDNAs into vectors for 
expression in yeast
To perform the Interaction Mating between TRIM proteins and 
Ubiquitin Conjugating Enzymes (UBE2), I cloned the cDNA of 26 of the best 
studies E2 enzymes (TABLE 2) in the pEG202 and pJG4-5 vectors; 42 TRIM 
cDNAs had already been cloned in both vectors (Reymond, Meroni et al. 
2001). I retrieve the cDNA sequences of known and novel UBE2 enzymes 
from genomic and expressed sequence databases (at web page 
www.ncbi.com). Then, as summarized in paragraph 3.1, I designed specific 
primers with restriction site-containing tails and I performed Polymerase 
Chain Reaction (PCR) experiments to amplify each UBE2 cDNA. After 
restricting fragments and plasmids, I performed a ligation reaction to clone 
the cDNA into the pEG202 plasmid and pJG4-5 plasmid.
pEG202 (Figure 10) (Gyuris, Golemis et al. 1993) is a yeast E.coli 
shuttle vector that contains a yeast expression cassette that include the 
promoter from the yeast ADH1 gene (PADH1), sequences that encode amino 
acids 1-202 of bacterial repressor protein LexA, which include the DNA 
binding and dimerization domains; downstream of the LexA coding region 
unique EcoRI, BamHI, Sail, Ncol, Notl, and Xhol cloning sites are present as 
well as the transcription terminator sequences from the yeast ADH1 gene 
(TADH1). It also contains an E.coli origin of replication (pBR ori), the 
ampicillin resistance gene (AmpR), a yeast selectable marker gene (HIS3), 
and a yeast origin of replication (2pm ori). UBE2 cDNAs have been inserted 
in frame with LexA into the unique restriction sites shown (Figure 10) to 
produce a LexA-UBE2 fusion protein.
pJG4-5 (Figure 11) (Gyuris, Golemis et al. 1993) is a yeast E.coli 
shuttle vector that contains a yeast expression cassette that includes the 
inducible promoter from the yeast GAL1 gene (Pgall), an ATG followed by 
105 codons encoding 9 amino acids from the SV40 large T nuclear
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localization signal, 87 amino acids that make up the activation domain B42, 
and 9 amino acids comprising the haemagglutinin (HA) epitope tag, and the 
transcription terminator sequences from the yeast ADH1 gene (TADH1). The 
plasmid also contains an E.coli origin of replication (pUC ori), the ampicillin 
resistance (AmpR), a yeast selectable gene marker (TRP1), and a yeast origin 
of replication (2pm ori) (Figure 11. UBE2 cDNAs have been inserted in 
frame with HA tag into the unique restriction sites shown (Figure 11) to 
produce a HA-B42-UBE2 fusion protein.
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TABLE 2
O fficial
Sym bol Other Alias Gene ID
UBE2A H H R6A, R A D 6A , U BC2 7319
UBE2B H R6B, U BC 2, R A D 6B, H H R 6B, E2-17K Da 7320
UBE2C R P3-447F3.1, U BC H 10, dJ447F3.2 11065
UBE2D1 E2(17)K B1, SFT, U BC 4/5, U BC H 5, U BCH 5A 7321
UBE2D 2 E2(17)K B2, P U B C 1, U BC 4, U BC 4/5, UBCH 5B 7322
UBE2D3 E2(17)K B3, M G C 43926, M G C 5416, U B C 4/5, UBCH5C 7323
U BE2D4 HBUCE1 51619
UBE2E1 UBCH 6 7324
UBE2E2 FLJ25157, U BCH 8 7325
UBE2E3 UBC H 9, U bcM 2 10477
UBE2F M G C105540, R G D 1307608 363284
UBE2G1 E217K , U BC 7, UBE2G  7326
U BE2G 2 1110003005R ik , D 10X rf369, U BC 7, Ubc7p 22213
UBE2H  E2-20K , U BG 8, U BC H , UBCH 2 7328
UBE2J1 CG I-76, H SPC 153, H SPC 205, N C U BE1, U bc6p 51465
UBE2K  AW 492011, D 5Ertd601e, E2-25k, H ip2, H ypg, Lig 53323
UBE2L3 E2-F1, L-UBC, U BC H 7, U bcM 4 7332
UBE2L6 M G C 40331, R IG -B, U BCH 8 9246
U BE2M  UBC-RS2, U BC 12, h U b cl2  9040
U BE2N UBC13 541130
UBE2Q1 G TAP, N ICE-5, PR O 3094, UBE2Q  55585
UBE2R1 cdc34 216150
UBE2S E2-EPF, E2EPF, EPF5 27338
UBE2T H SPC150, PIG50 29089
UBE2V1 CROC1; AI256840; 0610011J09Rik; U b e2v l 66589
U BE2V2 M M S2, U EV-2, U EV2 7336
List of Ubiquitin Conjugating Enzymes used in the Interaction Mating assays.
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The pEG202 vector. pEG202 is a multicopy yeast plasmid containing the yeast expression cassette with 
the promoter of the yeast ADH1 (ADH1 promoter), followed by sequences that encode amino acids 1- 
202 of bacterial repressor protein LexA. It also contains ADH1 terminator, a yeast origin of replication 
(2pm ori), a yeast selectable marker (HIS3), the ampicillin resistance gene (AmpR) and an E. coli 
origin of replication (pBR ori)
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Figure 11
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The pJG4-5 vector. pJG4-5 is a yeast E.coli shuttle vector that contains a yeast expression cassette with 
the promoter of the yeast GAL1 gene (P GAL), followed by sequences that encode the 106 amino acid 
fusion moiety that includes the nuclear localization signal from SV40 virus large T antigen, the B42 
transcription activation domain, and the haemagglutinin (HA) epitope tag. This plasmid also includes 
an E.coli origin of replication (pUC ori), the ampicillin resistance (AmpR), a yeast selectable marker 
gene (TRP1), a yeast origin of replication (2 pm ori) and the transcription terminator sequences from 
the yeast ADH1 gene (T ADH1).
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3.2.2 DNA transformation in yeast
The yeast culture was grown in 100 ml of YPD medium (lOg yeast 
extract, 20g peptone, 900ml of deionised H2 0) at 30°C, with shaking (150 
r.p.m.) to an OD6 0 0  of 1.0, corresponding to about 3 x 107  cells/ml. Yeast 
cultures were centrifuged at 3500 r.p.m. for 5 minute and the supernatant was 
poured off. Cells were washed in 10 ml of sterile water and centrifuged again 
at 3500 r.p.m. for 5 minute. Then, the yeast pellet was resuspended in 5 ml of 
sterile LiOAc buffer (0.1M LiOAc, lOmM Tris-HCl pH 8.0, ImM EDTA); 
cells were centrifuged and the supernatant poured off. The pellet was 
resuspended in 2 ml of sterile LiOAc buffer; DMSO was added to 10% final 
concentration. 50pl of this suspension was aliquoted into sterile 
microcentrifuge tubes containing lp l of plasmid DNA and 2.5pi of carrier 
DNA (single-stranded salmon sperm DNA). After adding 300pl of 40% 
PEG4000 in LiOAc buffer, the tubes were incubated at 30°C for 30 minute. 
Cells were heat shocked at 42°C for 15 minute and then were plated on 
100mm Petri dishes.
PJG4-5, encoding TRP1, was introduced into yeast strain EGY48 
(MATa, TRP1', his3' and Leu ) and trasformants were selected on glucose 
plates lacking tryptophan (glue -trp plates) (6.7 g yeast nitrogen base without 
tryptophan, 20g agar, 850 ml sterile H2 0, 10ml sterile glucose 20%). Instead, 
pEG202, encoding HIS3, was introduced in yeast strain EGY42 (MATa, 
HIS3", trpl' and Leu') and along with a URA3 lacZ reporter, pSH18-34, and 
trasformants were selected on glucose plates lacking uracile and histidine 
(glue -ura -his plates) (6.7 g yeast nitrogen base without uracile and histidine, 
20g agar, 850 ml sterile H2 0,10ml sterile glucose 20%).
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3.2.3 Yeast Cell lysates
For every TRIM and UBE2 protein transformed in both EGY42 and 
EGY48 yeast strain, a single colony was picked from the specific plate and 
resuspended in 1 0  ml of selective dropout media overnight (o.n.) in a 
microcentrifuge tube. For EGY42 transformants glucose medium lacking 
uracile and histidine was used (6.7 g yeast nitrogen base without uracile and 
histidine, 850 ml sterile H2 0, 10ml sterile glucose 20%); instead, for EGY48 
transformants galactose medium lacking tryptophan was used (6.7 g yeast 
nitrogen base without tryptophan, 850 ml sterile H2 0, 10ml sterile galactose 
20%).
Yeast culture was grown to 5 O.D.600, spinned for 2 minute, and 
supernatant was decanted. 200[il of SUTEB buffer (1% SDS, 8 M Urea, 
lOmM Tris pH 8 , lOmM EDTA, 0.01% bromophenol blue) was added 
together with protease inhibitor (SIGMA; 5pl/ml); then, 100pi of 0.5mm 
Acid Washed Glass Beads (SIGMA) was added and they were vortexed 3 x 
45 sec in microcentrifuge. The samples were incubated for lOmin at 65°C and 
the lysate was removed from the beads to a new 1.5ml eppendorf tube. They 
were centrifuged for 5 min at 12,000 rpm and supernatant was transferred into 
a new 1.5ml eppendorf tube. A Western Blot (WB) analysis (see paragraph 
3.3.3) was performed using anti-LexA (Roche) and anti-HA (Roche) 
antibodies.
3.2.4 Interaction mating assay
Individual EGY48 transformants were streaked on to standard 100mm 
Glu -trp plate in parallel lines, six or seven in a plate (Figure 12) by 
applicator sticks. Likewise, individual EGY42 transformants were streaked on 
Glu -ura -his plates in parallel lines (Figure 12). Plates were incubated at 
30°C over night (o.n.). The day after, the EGY48 derivatives and the EGY42
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derivatives were pressed onto the same replica velvet, so that the streaks from 
the two plates were perpendicular to each other, and each imprint is lifted 
with a YPD plate.
The YPD plates were incubated for 12-20 hr at 30°C, during which time 
diploids form at the intersections of the two plates.
Replica was done from the YPD plate to the following plates:
1. Glucose plates containing X-gal substrate, but lacking uracile, histidine and 
tryptophan (glue +X-Gal -ura -his -trp) (6.7 g yeast nitrogen base without 
uracile, histidine and tryptophan, 20g agar, 850 ml sterile H2 0, 10ml sterile 
glucose 20%, 20 pi X-Gal 50mg/ml).
2. Galactose and raffinose plates containing X-gal substrate, but lacking 
uracile, histidine and tryptophan (gal/raf +X-Gal -ura -his -trp) (6.7 g yeast 
nitrogen base without uracile, histidine and tryptophan, 20g agar, 850 ml 
sterile H2 0,10ml sterile glucose 20%, 10ml sterile raffinose 10%, 20 pi X-Gal 
50mg/ml).
3. Glucose plates, lacking leucine, uracile, histidine and tryptophan (glu -leu - 
ura -his -trp) (6.7 g yeast nitrogen base without uracile, histidine, tryptophan 
and leucine, 20g agar, 850 ml sterile H2 0,10ml sterile glucose 20%).
4. Galactose and raffinose plates, lacking leucine, uracile, histidine and 
tryptophan (gal/raf -leu -ura -his -trp) (6.7 g yeast nitrogen base without 
uracile, histidine, tryptophan and leucine, 20g agar, 850 ml sterile H2 0, 10ml 
sterile glucose 2 0 %, lml sterile raffinose 1 0 %).
They were incubated at 30°C and examined them after one, two, and three 
days. Interactors turned blue on X-Gal plates, and grew on gal/raf plates 
lacking leucine (Figure 12).
68
Figure 12
EGY42 strain expressing bait EGY48 strain expressing activation
protein (His+) tagged protein (TRP1)
YPD
3.gluc -leu -ura -his -trp 4.gal/raf -leu -ura -his -trpl.gluc +X-Gal -ura -his -trp 2.gal/raf +X-Gal -ura -his -trp
The Interaction M ating technique. Legends are as follow: 1. Glucose plates containing X-gal 
substrate, but lacking uracile, histidine and tryptophan (glue +X-G al -ura -his -trp); 2. 
G alactose and raffinose plates containing X-gal substrate, but lacking uracile, h istidine and  
tryptophan (gal/raf +X-Gal -ura -his -trp); 3 . G lucose plates, lacking leucine, uracile, 
histidine and tryptophan (glu -leu -ura -his -trp); 4. G alactose and raffinose plates, lacking  
leucine, uracile, h istidine and tryptophan (gal/raf -leu -ura -his -trp) (for details see the text).
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3 3  Cell culture and immunoblot
3.3.1 Cloning the UBE2 cDNAs in vectors suitable for transfection in HEK293 
and HeLa cells.
To transfect the UBE2 enzymes in HEK293 and HeLa cells, I cloned 
the cDNA of the UBE2 enzymes, which are have already been shown in the 
TABLE 2, both in the pcDNA3HA vector and in the pcDNA3myc-GFP 
vectors suitable for expression in mammalian cells ad easy detectable through 
the use of the tags. TRIM proteins were already available in both vectors 
(Reymond, Meroni et al. 2001).
pcDNA3 is a 5446 bp vector for the expression of the proteins in 
mammalian cells (Figure 13). It contains a mammalian expression cassette 
that includes the Human Cytomegalovirus (CMV) immediate-early 
promoter/enhancer, which permits efficient, high-level expression of 
recombinant proteins (Jalanko, Kallio et al. 1989). It also contains the 
Neomycin resistance gene that induces a selection of stable transfectants in 
mammalian cells and the SV40 early promoter and origin, which allows 
efficient, high-level expression of the neomycin resistance gene and episomal 
replication in cells expressing SV40 large T antigen. Moreover, the pcDNA3 
vector contains the SV40 early polyadenylation signal, which is necessary for 
an efficient transcription termination and polyadenylation of mRNA, a pUC 
origin that allows a high-copy number replication and growth in E.coli and an 
ampicillin resistance gene ((3-lactamase) which is important for the selection 
of vector in E.coli. In the pcDNA3-HA and pcDNA3myc-GFP the HA and 
myc-GFP tag respectively are present upstream the multiple cloning site that 
allows to clone the UBE2 cDNA in frame with the tags.
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The pcDNA3 vector. pcDNA3 is a vector for expression of proteins in mammalian cells. It has a 
mammalian expression cassette that includes the Human Cytomegalovirus (CMV) promoter/enhancer, 
a Neomycin resistance gene, the SV40 early promoter and origin. pcDNA3 vector also contains the 
SV40 early polyadenylation signal, a pUC origin that allows growth in E.coli and an Ampicillin 
resistance gene.
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3.3.2 Cell Culture and transient transfection
HeLa and HEK293T cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) 
Invitrogen, lOOU/ml penicillin/streptomycin and 2mM Glutamine, and split 
1:3 every three-four days. Cells were transfected using the Ca2+phosphate 
transfection method. Typically, lOfxg plasmid DNA was used and 60jxl CaCl2  
2M, 500pl 2 X HBS solutions, and lO i^l PO4. After mixing solution A 
(cDNA, Ca2+, H20  to 13pi final volume) to solution B (2 X HBS, P 04), CaCl2  
was added (15-20 min at Room Temperature). Then, DNA/Ca2+phosphate 
suspension solution was dropped to each 100mm Petri dish containing 
1,000,000 cells in a total volume of 9 ml, and they were incubated over night 
(o.n.) in a 5 % C 0 2  incubator.
3.3.3 Immunoblot analysis
Polypeptides separated by SDS/PAGE were transferred to a Hybond-P 
polyvinylidene difluoride (PVDF) transfer membrane optimised for protein 
transfer (Amersham Pharmacia Biotech), using a wet blotter (Biorad). After 
blocking with 5% skim milk in 20 mM Tris pH 7.4 and 150 mM NaCl 
containing 1% Tween 20, the membranes were probed with the primary 
antibodies at the dilutions indicated: mouse anti-HA antibody (1:1000; 
Roche), rabbit anti-LexA (1:1000, Sigma) mouse anti-Myc antibody (1:1000, 
Santa Cruz), sheep anti-MBP (1:1000, Santa Cruz), or rabbit anti-ubiquitin 
(1:5000; Bethyl Laboratory). Blots were washed three times with Tris- 
buffered saline/ Tween 20 0,1% and incubated with either peroxidase- 
conjugated anti-mouse IgG antibody (1:3000, GE Healthcare), anti-rabbit IgG
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antibody (1:3000, GE Healthcare) or anti-sheep IgG (1:3000, GE Healthcare), 
then developed with a chemioluminescence detection system (ECL, BioFX 
Laboratories).
3.4 Immunofluorescence
Hela cells were seeded on glass cover slips in 12-multi well plates 
(Sarsted) the day before transfection with Lipofectamine 2000 (Invitrogen) to 
obtain low expression level. Twenty-four hours after transfection the cover 
slips were washed in cold PBS and cells were fixed with 4% 
paraformadehyde in PBS for 5 min. Cells were then permeabilized in 0.5% 
Triton-X-100 in PBS for 10 min. Non-specific binding sites were blocked by 
incubating with 5% Bovine Serum Albumine (BSA), 0.1%Tween in PBS for 
1 hour. Cover slips were then incubated with anti-HA monoclonal antibody 
(1:500, Roche) for 2 hours. After washing, cover slips were incubated with 
Cy3-conjugated anti-mouse secondary antibody (1:100, Jackson laboratories). 
Slides were mounted using Vectashield with DAPI (Vector Laboratories); 
images were acquired both on LeicaDM2500 and processed with the Leica 
Application Suite V3 software and on Nikon confocal D-Eclipse Cl imaging 
microscope with Nikon software and processed either as grey scale or dual 
colour TIFF images in Adobe Photoshop (Adobe Systems).
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3.5 MBP-TRIM protein expression and purification
3.5.1 Cloning the TRIM cDNAs in vectors suitable for expression in E.coli
TRIM1, TRIM9, TRIM11, TRIM18, TRIM27 and TRIM32 were 
cloned in pMal c2x vector (NEB Biolabs) as indicated in 3.1 paragraph, 
which encodes maltose binding-protein (MBP), resulting in the expression of 
MBP-TRIM fusion proteins in E.coli (Duplay, Bedouelle et al. 1984).
pMAL-c2x is a 6646 bp vector for the expression of the proteins in 
prokaryotic cells (Figure 14). The pMAL-c2X vector contains the strong 
“tac” promoter, the ampicillin resistance that is necessary for the selection of 
the vector in E.coli strain and the malE gene, which encodes maltose-binding 
protein (MBP), fused to the lacZa gene. Restriction sites between malE and 
lacZa are available for inserting the cDNA selected and insertions usually 
inactivate the (3-galactosidase a-fragment activity of the malE-lacZa fusion. 
This results in a blue to white colour change on Xgal plates when the 
constructs are transformed into an a-complementing host such as TB1 or 
JM107 strain. The vector also carries the laclq gene, which encodes for the 
Lac repressor. This keeps expression from Ptec low in the absence of IPTG 
induction. Moreover, the pMAL-c2X vector also contains the sequence 
coding for the recognition site of Factor Xa protease, located just 5’ to the 
poly linker insertion sites. This allows MBP to be cleaved from the protein 
after purification.
All TRIM genes are inserted downstream from the malE gene of the E.coli 
resulting in the expression of an MBP-TRIM fusion protein.
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Figure 14
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The pMAL-c2X vector. pMAL-c2x is a vector for expression of proteins in prokaryotic cells. It has the 
strong “tac” promoter , the malE gene which encodes for the Maltose Binding Protein (MBP) and lacl9 
gene, which encodes for the Lac repressor. It also contains the Ampicillin resistance gene and the 
sequence coding for the recognition site of Factor Xa protease.
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3.5.2 MBP-TRIM protein expression and purification
The DNA of the recombinant MBP-TRIM constructs was transformed 
into E.coli Rosetta (DE3) cells as indicated in 3.1.4 paragraph. Cells from 
single colonies were grown in LB broth (10 mL) supplemented with 
ampicillin (100pg/mL) and chloramphenicol (100pg/mL). After an over night 
(o.n.) of growth at 37°C, the OD600 was measured and the cultures were 
diluted to a final OD600 of 0.1 in 1L of fresh LB containing ampicillin and 
chloramphenicol at the same concentration indicated above. For each TRIM 
proteins, the cultures were grown for 3.5 hr at 37°C and simultaneously 
induced with 0.1 mM isopropyl (3-d-thiogalactoside (IPTG) when the OD600 of 
all cultures was 0.6-0.8. Before adding IPTG, a lOOpl aliquot was removed 
for Western Blot analysis. The pellet was resuspended in 50pl of sample 
buffer (250 mM Tis-HCl pH 6.8, 2% SDS, 10% Glycerol, 0.002% 
Bromphenol Blue). Cell cultures were grown at 24°C o.n. Cell cultures were 
then cleared using a JA-12 Beckman rotor (5,000 rpm, 20 min, 4°C) and cell 
pellets were resuspended in 40 mL of Lysis Buffer containing 50 mM Tris- 
HC1 (pH 7.5), 500 mM NaCl, 0.5 mM (3-mercaptoethanol and ImM 
Benzamidine. Resuspension was achieved by agitating the Beckman 
centrifuge tubes containing the cells and the buffer on a shaker for 15 min at 
600 rpm. The centrifuge tubes were incubated on ice (30 min) and sonicated 
at 4°C three times (40 sec, 50% amplitude of Misonix 3000 sonicator). Cell 
lysates were cleared using a JA-12 Beckman rotor (11,000 rpm, 40 min, 4°C) 
and proteins were purified using an amylose-bound chromatography. The 
columns were washed three times with Lysis buffer and the proteins were 
eluted by addition of an elution buffer containing: 50 mM Tris HC1 pH7.5, 
500 mM NaCl, lOmM Maltose, 5mM (3-mercaptoethanol. MBP-TRIM 
proteins were separated on SDS-PAGE (10% gels) and visualized with 
Coomassie blue staining.
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3.6 MBP pull-down assay
In order to bound MBP-TRIM proteins to amylose beads, 4pg MBP- 
TRIM protein or lpg MBP protein was incubated with 20pl of amylose beads 
(New England Biolabs) in 50mM Tris-HCl pH 7.5 at 4°C for 2 hours. The 
beads were then harvested (3300 rpm, 3 min, 4°C) and washed three times 
with Lysis Buffer (20 mM Tris pH7.5, 20% Glycerol, 50mM NaCl, 5mM 
EDTA pH 8 , 0.1% Triton, 1.5mM PMSF and 1 mg/ml aprotin, leupeptin and 
pepstatinat). A lOpl aliquot of the mixture was removed for Western Blot 
analysis and amylose-MBP-TRIM proteins were visualized with Coomassie 
blue staining. Afterwards, each amylose-MBP-TRIM proteins was incubated 
with 5pg of HEK293T crude extract transiently transfected with MycGFP- 
UBE2 enzymes at 4°C for 4 hours in Lysis Buffer. The beads were harvested 
and washed three times with Lysis buffer; bound proteins were separated on 
SDS-PAGE and UBE2 were visualized with immunoblotting using the anti- 
Myc antibody (see paragraph 3.3.3).
3.7 In vitro Ubiquitylation assays
The in vitro ubiquitylation assays were carried out in a volume of 15 
pL containing 34 nM Ubal (Human Recombinant, Ron T.Hay’s lab), 0.8 jliM 
E2-conjugating enzyme (Human Recombinant, Ron T. Hay’s lab), 35 nM 
ubiquitin (Boston Biochem), 5 mM MgC12, 2 mM ATP, 150 mM NaCl, 150 
mM TCEP, 0.1% NP40 and 2.2 pM MBP-TRIM protein in 50 mM Tris-HCl 
pH7.5. MBP protein was used at 2 jllM. After incubation at 37°C for 2 hrs, the 
reactions were terminated by the addition of Loading buffer (see above) and 
analysed by SDS-PAGE (10% gels). Immunoblots using anti-Ubiquitin and 
anti-MBP antibodies were performed.
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3.8 In vivo Ubiquitylation assays
HEK293T cells were co-transfected with HA-Ubiquitin (Stefano 
Gustincich’s lab) and MycGFP-TRIM proteins. When applicable, 42 hrs after 
transfection the culture medium was replaced with fresh medium containing 
MG132 proteasome inhibitor (Sigma) at a final concentration of 20 pM and 
the cells were further cultured for 6  h. The total cell lysate was prepared in 
RIPA buffer (50 mM TRIS-HC1 pH 8 ,0.1% SDS, 150 mM NaCl, 0.5% DOC, 
1% NP-40, 1.5 mM PMSF and 1 mg/ml aprotinin, leupeptin and pepstatin). 
DNA in the sample was sheared with a 22-gauge needle and the lysate was 
centrifuged using a Sigma 12024H rotor (13000, 30 min, 4°C). The 
supernatant was then incubated with lpg anti-Myc antibody (9E10 Santa- 
Cruz) over-night at 4°C. After adding protein A-Sepharose beads (Sigma), 
complexes were pelleted and washed 4 times with lysis buffer. 
Immunoprecipitates were separated on SDS-PAGE (10% gels) and analyzed 
by Immunoblotting.
3.9 In vitro SUMOylation assays
The in vitro SUMOylation reactions were performed at 37°C for 4 
hours in a 20 pi reactions containing 34 nM SAE1/SAE2 (human 
recombinant, Ron T .Hay’s lab), 0.4 pM Ubc9 (human recombinant, Ron 
T.Hay’s lab), 2.2 pM MBP-TRIM protein or GST-PML (human recombinant, 
Ron T.Hay’s lab) protein in 50 mM Tris-HCl pH7.5 and 32 pM SUMO 1 or 
SUM02 (Ron T. Hay’s lab). The reaction buffer contained 50 mM Tris-HCl 
pH7.5, 5 mM MgC12, 2 mM ATP, 150 mM NaCl, 2.5 mM DTT, 0.1% NP40. 
The reactions were terminated by the addition of Loading buffer (see above) 
and analysed by SDS-PAGE (4-12% gradient gels). Immunoblots using anti- 
SUMOl, anti-SUM02 and anti-MBP antibodies were performed.
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CHAPTER 4: RESULTS
4.1 Preliminary screening of TRIM proteins and Ubiquitin Conjugating 
Enzymes interactions performed through Interaction Mating.
To act as Ubiquitin Ligase or E3 the interaction with the Ubiquitin 
Conjugating Enzyme or UBE2s is required. Therefore, I preliminary tested 
the interaction between TRIM proteins and UBE2 proteins through the 
Interaction Mating technique, as a first evidence for a putative E3 role of 
TRIM proteins.
4.1.1 Interaction Mating assay
The yeast Interaction Mating is a form of two-hybrid system to test 
interaction between known proteins and it offers a number of advantages over 
biochemical methods such as quickness and sensibility.
The two-hybrid approach takes advantage of the modular domain 
structure of eukaryotic transcription factors. They usually have at least two 
distinct functional domains: one that directs binding to specific DNA 
sequences and one that activates transcription (Finley and Brent 1994). This 
modular structure is best illustrated by yeast experiments showing that the 
DNA binding domains or activation domains can be exchanged from one 
transcription factor to the next and retains function.
The Interaction Mating has three basic components:
• A yeast vectors for expression of a known protein fused to a DNA 
binding domain (LexA)
• A yeast vector for expression of a known protein fused to a 
transcription activation domain (B42)
• Yeast reporter genes that contain binding sites for the DNA binding
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domain (LexA responsive elements)
The system I used utilizes a yeast strain with two reporter genes. One 
reporter is a yeast LEU2 derivative that has its normal upstream regulatory 
sequences replaced with LexA operators. Transcription of the LexA-operator- 
LEU2 gene (LexAop-LEU2) is measured by the ability of the strain to grow in 
the absence of leucine, which requires the LEU2 gene product. The LexAop- 
LEU2 gene is integrated into the yeast chromosome. The other reporter gene 
is lacZ, which provides a secondary assay of activation. When the 
transcription of lacZ gene is activated, the strain is able to form blue colonies 
on X-Gal medium.
The Interaction Mating technique takes advantage of the fact that 
haploid cells of the opposite mating type will fuse to form diploids when 
brought into contact with each other. The activation-tagged protein is 
expressed in one yeast strain mating type (e.g. MATa) and the bait is 
expressed in a second strain of the opposite mating type (e.g. MATa). When 
the two strains are mixed on the same plate, they form diploids in which the 
bait and activation-tagged proteins have the opportunity to interact and 
activate the reporter genes. The interaction is measured as activation of the 
LexAop-LEXJ2 and LexAop-la.cZ reporters.
The bait protein is constitutively expressed from the pEG202 plasmid. 
It binds to LexA operators upstream of the reporter genes, LEU2 and lacZ, 
but does not activate transcription per se.
The activation-tagged cDNA encoded protein is conditionally 
expressed from the GAL 1 promoter. In glucose medium (Figure 15a) the 
activation tagged cDNA encoded protein is not made because the GAL1 
promoter is repressed. The yeast does not grow in the absence of leucine and 
forms white colonies on X-gal plates. Instead, when the yeast is grown in 
galactose medium, activation tagged cDNA encoded protein is expressed 
(Figure 15b and Figure 15c). If the bait interacts with the activation-tagged 
cDNA encoded protein, the activation domain is tethered to the DNA and
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activates the reporter genes. The cells form colonies on a medium lacking 
leucine and form blue colonies on an X-gal plate (Figure 15b). Instead, if the 
bait does not interact with the activation-tagged cDNA encoded protein, the 
cells do not grow on a medium lacking leucine and form white colonies on X- 
gal plate (Figure 15c).
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Figure 15
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Schematic representation of the Interaction Mating. A) Glucose medium. The LexA fusion protein 
(bait) is made and binds to LexA operators upstream of the two reporter genes, LEU2 and lacZ. The 
activation-tagged cDNA encoded protein is not expressed because the GAL1 promoter is repressed in 
the presence of the glucose. B) Galactose medium: interaction. Galactose induces expression of an 
activation-tagged cDNA encoded protein that does not interact with bait protein and no activation of 
the gene is observed. C) Galactose medium: no interaction. Galactose induces expression of an 
activation-tagged cDNA encoded protein that does not interact with bait protein.
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4.1.2 Western Blot analysis of both TRIM and UBE2 protein expression in 
yeast cell
A Western Blot analysis of TRIM proteins and UBE2 enzymes 
cloned both in the pEG202 and in the pJG4-5 vectors was performed 
before all the Interaction Mating experiments to verify the expression 
of the fusion proteins in the yeast strains.
The monoclonal anti-LexA antibody was used to specifically 
recognize the LexA tag of the pEG202 vector. The Western Blot 
assays performed with anti-LexA antibody showed bands of the 
expected size for both LexA-TRIM (60/100KDa) and LexA-UBE2 
(38/48KDa) fusion proteins (Figure 16a). Instead, the anti-HA 
antibody specifically recognized the HA epitope tag present in the 
pJG4-5 vector. Western Blot analysis performed with anti-HA 
antibody showed bands of the expected size for both B42-HA TRIM 
(50-90 KDa) and B42-HA UBE2 fusion proteins (28/32KDa) (Figure 
16b). Consistently, the Western Blot performed to verify the 
expression of TRIM proteins in yeast lysates confirmed what already 
reported by Reymond and collaborators (Reymond, Meroni et al. 
2001).
Thus, Western Blot analysis showed that both TRIM and UBE2 
fusion proteins were efficiently expressed from both vectors.
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Western Blot analysis of TRIM and UBE2 proteins expressed in yeast cells. Here I reported two 
Western Blot scans that are representative of all Western Blot analysis performed to test both TRIM 
and UBE2 fusion protein expression in yeast lysates, (a) Western Blot performed using anti-LexA 
antibody upon a selection of UBE2 enzymes (Molecular Weight: 38-48KDa). (b) Western Blot 
performed using anti-HA antibody upon a selection of TRIM proteins (Molecular Weight: 56-85 KDa). 
Red asterisks indicate B42-HA TRIM proteins molecular weight.
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4.1.3 The Interaction Mating assay between UBE2 enzymes and TRIM 
proteins
Thanks to the Interaction Mating technique, I tested 42 TRIM proteins 
(www.trimbase.tigem.it) expressed both as bait and as pray in the yeast strain 
EGY48 (mating type a) and in the yeast strain EGY42 (mating type a) 
against almost 26 UBE2 proteins (see TABLE 2) expressed in both vectors 
and yeast strains.
To be certain of the interactions observed between the TRIM proteins 
and the UBE2 enzymes, I repeated the Interaction Mating assays seven times 
with freshly transformed TRIM and UBE2 pEG202 and pJG4-5 constructs in 
yeast strain every time (see paragraph 3.2.1). I summarized the results of the 
Interaction Mating assays in TABLE 3. This analysis revealed more than 100 
interactions and demonstrated that the majority of TRIM proteins tested 
interact with one or more UBE2 enzymes (TABLE 3) (see example of 
Interaction Mating in Figure 17). Numerous interactions were observed with 
the D (Dl-4) and E (E l-3) families of UBE2 enzymes while several TRIM 
proteins also showed binding to UBE2N. Two peculiar interactions were also 
observed: i) an exclusive binding between TRIM9 and UBE2G2 and ii) the 
interaction of TRIM32, beside the D and E classes and UBE2N, with 
UBE2V1 and UBE2V2 (TABLE 3). The UBE2 and the TRIM proteins were 
properly expressed in yeast and lack of the reporter activation mainly 
underlies real UBE2 selection. Inclusion of UIP48, a RING finger-containing 
protein able to interact with UBE2L3 and UBE2L6 but not with the D and E 
families, demonstrated the specificity of the interactions observed (Martinez- 
Noel, Muller et al. 2001). In some cases however, lack of an interaction may 
represent intrinsic flaws in the yeast two-hybrid experiment. Indeed, 
compared to the classical techniques used to evaluate protein-protein 
interactions (for details see DISCUSSION chapter), the main criticism 
applied to the yeast two-hybrid screen is the high number of false negative.
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Many natural protein-protein interactions cannot be detected using the yeast 
two-hybrid method. Some proteins do not interact in the environment of the 
yeast nucleus, such as proteins of the secretory compartments that require 
oxidative conditions or glycosylation for proper folding. Integral membrane 
proteins are unlikely to work in the context of reconstituted transcription 
factor and many interactions are triggered by post-translational modifications 
not available in yeast. In addition, another important limitation in the usage of 
the yeast two-hybrid approach is the possibility of false positive interactions. 
The reason for this error rate lies in the principle of the screen: the assay 
investigates the interaction between overexpressed fusion proteins in the yeast 
nucleus. It is well demonstrated that overexpression can result in non-specific 
interactions and some proteins might specifically interact when they are co­
expressed in the yeast, although in reality they are never present in the same 
cell at the same time. As a consequence of these specific issues, independent 
verification through other alternative techniques (i.e. Co- 
immunoprecipitations, in vitro pull down, Mass spectroscopy, etc.) of a 
putative protein-protein interaction is essential.
However, the yeast two-hybrid has demonstrated its power by its 
methodological diversity and technical simplicity to rapidly generate a large 
amount of reliable protein-protein interaction data. The strength of yeast two- 
hybrid system is its ability to identify direct interactions and also to detect 
interactions of lower affinity, which are rather transient.
Thus, since the transient nature of E3/E2 interactions, the yeast 
Interaction Mating approach resulted as the finest technique to investigate 
putative TRIM/E2 interactions. Even if I confirmed all the TRIM/E2 
interactions seven times, as reported in TABLE3, I can not exclude the 
presence of eventually both false positive and false negative interactions.
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Examples of Interaction Mating. A) Interaction Mating assay in which I tested interactions between 
TRIM proteins and UBE2 enzymes. The interaction is given by colonies turning blue on Galactose/ 
Raffinose (gal/raf) +X-Gal plates. B) Interaction Mating assay in which I tested interaction between 
UIP48 and UBE2L3/L6. TRIM proteins are used as control. The interaction is given by colonies 
turning blue on gal/raf +X-Gal plates and colonies growing on Gal/raf -leu plates (for details see the 
text). The Interaction Mating screen was repeated seven times. The pictures reported above are 
representative of the results obtained
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TABLE 3
TRAI1
TRM2
TR1M3
TRAM
TRttiS
TRJM6
TRM7
TRIMS
TR1W9
TRftltO
TR1M11
TRW12
TRJM13
TR1M14*
TRIM15
TR1M16'
TR1M17 
TRIM 18 
TRIM19 
TRIM20- 
TRftCJ 
TPM22 
TRIM23 
TR1M24 
TR1M25 
TPJM26 
TRM27 
TR1M28 
TR1U2S* 
TRIM30 
TR1M31 
TR1M32 
TRIM37 
TRIM39 
TRIM4C 
TRIM42 
TRIM43 
TRIM44' 
TRIW45 
TRIM46 
TR1W48 
TRIM50 
TR1M52 
LKP48
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Schematic representation of the results obtained with the yeast Interaction Mating screening. To 
assure the experiments’ reproducibility, I repeated the Interaction Mating experiments seven times. 
The TRIM and the UBE2 (E2) clones tested are indicated; the letters below the E2s indicate the 
direction of the two-hybrid experiments: a, B42-BD and b, LexA-DBD. The asterisk indicates the 
RING-less TRIM proteins. The interaction strength and reproducibility are indicated by arbitrary 
scored in the range 0-1, represented also by the colour-scale shown at the bottom, which was calculated 
as the fraction of detected interactions on the number of the experiments (seven performed for each 
pair tested) multiplied by 0.5 if the interaction was observed with only one reporter gene. Grey cells 
indicate no interaction; white cells indicated non-tested pairs.
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4.1.4 TRIM proteins interact with UBE2 enzymes through their RING domain
It is known that the RING domain underlies ubiquitin ligase activity by 
directly binding the UBE2 enzymes. This key-role was definitely provided by 
the crystal structure of Cbl RING domain bound to UbcH7/UBE2L3 (Zheng, 
Wang et al. 2000) and then by the NMR analyses of the BRCA1 and CNOT4 
complexed with UbcH5/UBE2D (Dominguez, Bonvin et al. 2004). 
Consistently, the Interaction Mating screening revealed the absence of the 
interaction between the 5 “unorthodox” TRIM members that lack the RING 
domain (Sardiello, Cairo et al. 2008) and the UBE2 enzymes (TABLE 3). 
Moreover, through the Interaction Mating I also analyzed TRIMl8 , TRIM32 
and TRIM50 mutants carrying individual deletions of relevant protein regions 
[R, B-boxes (BB), CC, RFP-like and N- or C-terminal regions; Figure 18] for 
the interaction with the UBE2 enzymes. As already reported in literature 
(Reymond, Meroni et al. 2001) deletion of the CC region resulted in the loss 
of self-association confirming that the CC region is necessary and sufficient 
for homo-interaction. Interestingly, deletion of the RING region resulted in 
loss of the interaction with UBE2 indicating that the RING region is involved 
in the interaction with UBE2 proteins (Figure 18a and Figure 18b). As 
shown in Figure 18, deletion of the BB-CC region and RFP region affected 
neither the homo-interaction nor the interaction with UBE2 proteins. In 
addition, the RING domain alone is able to interact with UBE2 proteins. 
Moreover, this analysis also demonstrated that the B-box domains, although 
structurally similar to the RING domain, were not intimately involved in the 
basic TRIM/E2 interaction.
Taken together these data indicate that the RING domain is therefore 
necessary and sufficient for the interaction between TRIM proteins and UBE2 
enzymes.
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Two-interaction mating panels showing either TRIM18 (A) or TRIM32 (B) domain deleted mutants, 
shown in the right scheme, against the UBE2 enzymes indicated. Blue colonies in X-gal plates (Xgal) 
and growth on plates lacking leucine (-leu) in the presence of Galactose/Raffinose (Gal/Raf) represent 
positive interactions.
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4.2 Validation of the interaction between TRIM and UBE2 proteins 
through MBP pull-down assays.
To validate the TRIM-UBE2 interactions observed through the 
Interaction Mating screening, I used the MBP pull-down technique. I chose to 
test TRIMl, TRIM9, TRIMl 1, TRIMl8 , TRIM27 and TRIM32 as 
representative members of the family since they recapitulated the most 
important interactions observed in yeast Interaction Mating screening.
4.2.1 MBP pull-down assay
MBP pull-down assay is an in vitro method used to determine a 
physical interaction between two or more proteins. The MBP pull-down 
technique has more advantages such as sensitivity and high accuracy; 
moreover, either the discovery or the confirmation of protein-protein 
interactions depends heavily on the nature of the interaction studied. 
Interactions can be stable or transient, and the characteristic determines the 
conditions for optimizing binding between the bait and prey proteins.
MBP pull-down uses an MBP-fusion protein (bait) bound to amylose- 
coupled beads to affinity purify any proteins (prey) that interact with the bait 
from a pool of proteins in solution. I chose to use TRIM proteins as bait and 
UBE2 enzymes as prey. Bait and prey proteins can be generally obtained 
from multiple sources including cell lysates, purified proteins, expression 
systems and in vitro trascription/traslation systems. In all my experiments I 
tested purified MBP-TRIM fusion proteins and MycGFP tagged-UBE2 
(MycGFP-UBE2) enzymes transiently transfected in HEK293.
91
4.2.2 Expression and purification of MBP-TRIM proteins
To produce MBP-TRIM proteins, I transformed the six pMAL-TRIM 
constructs (TRIMl, TRIM9, TRIM11, TRIM18, TRIM27, TRIM32) in E. 
coli Rosetta cells that were grown at 37 °C as indicated in paragraph 3.5. 
When E. coli cells harbouring the recombinant genes were induced with 150 
pM of IPTG for approximately 5 hours, all fusion MBP-TRIM proteins were 
markedly overproduced (Figure 19-second lane for each MBP-TRIM protein 
gel). Coomassie-stained gel analysis of the crude extracts indicated that the 
fusion proteins with the expected molecular mass accounted for 20-30% of 
the total cell proteins. Even if all MBP-TRIM proteins were mainly detected 
in the insoluble fraction (60%) than in the soluble one (40%) (Figure 19-third 
and fourth lanes MBP-TRIM protein gel), the amount and the purity of the 
MBP-TRIM proteins produced were sufficient for the biochemical assays 
performed. In all cases, improper bands may result from high-molecular- 
weight aggregate or truncated fragment.
The fusion proteins were further purified with the amylose resin. 
Coomassie-stained gel analysis of the eluted fraction revealed that procedures 
whereby MBP-TRIM proteins were bound to the column, washed and eluted, 
led to their recovery in the 60% pure form. Finally, I appropriately 
concentrated (2 mg/ml) all TRIM protein pure forms for further biochemical 
assays.
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Figure 19
M BPTR 1M 1
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MBPTRIM9
122KDa
MBPTRIM11
94KDa
Coomassie gel staining of high-level expression and purification of TRIM proteins fused to MBP. (A) 
MBP-TRIM1. Lanes are: 1, un-induced MBP-TRIM1 (UI); 2, induced MBP-TRIM1 (I); 3: insoluble 
fraction of the crude extracts (Ins); 4: Soluble fractions of the crude extracts (Sol); 4: column eluted 
MBP-TRIM1; M: molecular weight standards in kDa. (B) MBP-TRIM9. See legend in A). (C) MBP- 
TRIM11. See legend in A). (D) MBP-TRIM18. See legend in A).
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(D) MBP-TRIM18. See legend in A). (E) MBP-TRIM27. See legend in A). (F) MBP-TRIM32. See 
legend in A).
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4.2.3 MBP pull-down experiments
To confirm the TRIM-UBE2 binding specificity, I used the MBP-pull 
down approach on a selection of TRIM and UBE2 enzymes representative of 
the entire spectrum of the interactions observed in the two-hybrid screening. 
In the assays, I chose TRIMl, 9, 11, 18, 27, 32 and 9 UBE2 enzymes (Dl, 
D2, D3, E l , N, L3, L 6 , G2, V I, V2).
MBP-fusion proteins immobilized on the beads were incubated with 
HEK293T crude lysates transiently expressing MycGFP-UBE2 enzymes and 
specific binding was revealed by immunoblot (Figure 20). UBE2D1, D2, D3, 
E l and N were captured by TRIMl, 11,18 and 32 confirming the interactions 
observed in yeast. Interestingly, TRIM27 binds only UBE2D1 and D3 but not 
the highly similar UBE2D2 that also showed a very weak interaction in yeast. 
TRIM9 only bound UBE2G2 confirming its highly unique interaction. As 
expected, no binding could be observed with UBE2L3 and L6 , reflecting the 
specific nature of TRIM-UBE2 interactions (Figure 20a). MBP-TRIM32 and 
MBP-TRIM 18 were also incubated with lysates of HEK293T cells transiently 
transfected with UBE2N, VI and V2. As also observed in yeast, TRIM32 also 
bound UBE2V1 and V2 in addition to UBE2N. As expected TRIM 18 bound 
UBE2N but was unable to bind UBE2V enzymes (Figure 20b). I repeated the 
experiments three times and every time I confirmed all the results .
Thus, the specific interaction of the selected TRIM proteins with 
defined UBE2 enzymes observed in yeast was validated by in vitro binding 
analysis.
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Figure 20
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MBP pull-down assay confirms UBE2 and TRIM proteins specific interactions. A) MBP pull-down 
analysis of eight MycGFP-UBE2 enzymes transiently expressed in HEK293T cells (D l, D2, D3, E l, N, 
G2, L3, and L6 as indicated) with six MBP-TRIM proteins (TRIMl, 9 ,1 1 ,1 8 , 27, and 32). MBP was 
used as control. Immunoblot with anti-Myc antibody of the input lysates is shown in the upper panel 
(Lysates). For each MBP-TRIM protein the anti-Myc immunoblot and the Comassie Blue staining of 
the gel are shown. B) MBP pull-down analysis of three MycGFP-UBE2 transiently expressed in 
HEK293T cells (N, VI and V2 as indicated) with MBP-TRIM32 and MBP-TRIM18. MBP was used as 
control. Legend as in A). The MBP-pull down experiments were repeated three times and every time 
all the TRIM-UBE2 specific interactions have been confirmed as highlighted in the picture above.
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43  In Vitro Ubiquitylation assay
To establish that selective UBE2 binding by TRIM proteins is translated 
into functional ubiquitin ligase activity, I performed in vitro ubiquitylation 
assays that test the ability of a putative E3 ligase to catalyze poly- 
ubiquitylation in vitro by means of different UBE2 enzymes. The in vitro 
ubiquitylation should result from mixing all the components required for the 
ubiquitylation reaction: ATP, ubiquitin peptide, E l and E2 enzymes and the 
candidate E3 ligase (see 3.7 paragraph).
Consistently, the above 6  MBP-TRIM proteins were incubated with all 
ubiquitylation cascade components. The immunoblot analysis of the reaction 
products using antibodies against ubiquitin revealed the presence of HMW 
polyubiquitylation species when the recombinant MBP-TRIM protein was 
added to the reaction mixture (Figure 22). To confirm that TRIM proteins are 
the essential E3 in the ubiquitylation assay performed, for each TRIM protein 
tested I set up incomplete mixtures containing different combinations of the 
reagents (ATP, Ubiquitin, E l enzyme, E2 enzyme and TRIM protein). The 
immunoblot analysis of the reaction products using both antibodies against 
ubiquitin (Figure 21-upper panel) and antibodies against the MBP-tag 
highlighted (Figure 21-lower panel) that lack of MBP-TRIM proteins as well 
as the above reagents did not result in the detection of the polyubiquitylation 
smear. This underlies that El enzyme, UBE2 enzyme and TRIM proteins are 
all required for in vitro ubiquitylation reaction.
Concomitantly, I also addressed the specific UBE2 usage in these 
reactions. The in vitro ubiquitylation assays were carried out in the presence 
of one of the following recombinant enzymes as UBE2: D l, D2, D3, E l, N, 
J2, G2, L3, L 6 . Figure 21a shows that incubation of MBP-TRIM 1, 11,18 and 
32 in the presence of either UBE2D1, D2, D3, E l, or N resulted in 
polyubiquitylation recapitulating the binding specificity observed in yeast and 
in MBP pull-down assays. Moreover, MBP-TRIM 11 acted as E3 also in the 
presence of UBE2J2 that was not present in the original two-hybrid panel. As
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expected from the binding data, MBP-TRIM27 displayed specific E3 activity 
in the presence of UBE2D1 and D3 but not with the non-interacting D2. The 
remarkable binding specificity of MBP-TRIM9 for UBE2G2 was also 
manifest in the functional assay where E3 ligase activity was only observed 
when TRIM9 was incubated in the presence of UBE2G2. Consistently with 
the specific data observed through the Interaction Mating screening, the 
incubation of MBP-TRIM proteins in the reaction mixture containing 
UBE2L3 and L 6  did not result in the formation of any polyubiquitylated 
species (Figure 22a).
As both yeast two-hybrid and MBP-pull down assays highlighted the 
interaction between TRIM32 and UBE2V, I tested TRIM32 
polyubiquitylation in the presence of ATP, recombinant E l enzyme, 
ubiquitin, recombinant UBE2N and VI proteins. It is known that VI is a non- 
autonomous UBE2 that lacks the catalytic cysteine (Cys) and can only act in 
cooperation with UBE2N. Consistently, TRIM32 was a more efficient E3 in 
the presence of both UBE2N and V1 than with UBE2N alone (Figure 22b - 
left panel).
I also analyzed the reactions with antibodies against the MBP portion of the 
protein, which showed that in the majority of the cases polyubiquitylated 
species are mainly represented by the MBP-TRIM proteins themselves 
(Figure 23b). The results with MBP-TRIM 1, MBP-TRIM11, MBP-TRIM18, 
MBP-TRIM32 perfectly matched the results obtained with the anti-ubiquitin 
antibody (Figure 23b and Figure 23c). This is not the case with MBP- 
TRIM9 and MBP-TRIM27 where I detected a reduced self- 
polyubiquitylation. It is possible that TRIM9 and TRIM27 might ubiquitylate 
other proteins present in the reaction mixture (El, UBE2 or E. coli proteins) 
more efficiently than they ubiquitylate themselves.
Taken together, these results indicate that TRIM proteins act as E3 ligases 
cooperating with the ubiquitylation machinery in a very specific manner that
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recapitulates the specific TRIM-UBE2 interactions observed both in 
Interaction Mating screening and by MBP-pull down assay.
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Control of the in vitro ubiquitylation assay. To confirm that TRIM proteins are the essential E3 in the 
ubiquitylation reactions, for each TRIM protein tested I set up incomplete mixtures containing 
different combinations of the reagents (ATP, Ubiquitin, E l enzyme, E2 enzyme and TRIM protein) as 
indicated in the figure. The reactions were repeated four times for each TRIM protein selected and 
analyzed by immunoblotting using anti-Ubiquitin (upper panel) and anti-MBP (lower panel) 
antibodies. Lack of TRIM proteins as well as of any other of the above reagents did not result in the 
detection of poly-ubiquitylation smear (lane 1-4). As a positive control, ubiquitylation was observed 
with the incubation of MBP-TRIM proteins with the complete mixture (lane 5). The picture reported 
above represents the results obtained in all four experiments.
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TRIM proteins act as ubiquitin E3 ligases in vitro using the interacting UBE2 enzymes. A) MBP-TRIM 
proteins (TRIM1, 9 ,11 ,18 , 27 and 32) were tested for E3 ligase activity in in vitro ubiquitylation assay 
in the presence of the UBE2 enzymes indicated (TRIM+D1, D2, D3, E l, N, G2, J2, L3, L6). As control, 
the assay was performed without the TRIM protein (lanes with only UBE2 indicated). Immunoblot 
with anti-Ubiquitin antibody to detect the ubiquitylated species is shown. B) In vitro ubiquitylnation 
assay using UBE2N and VI in the combination indicated in the presence of MBP-TRIM32. In vitro 
Ubiquitylation assays were repeated four times for all the TRIM proteins tested in the same order 
reported in the picture above that is representative of all the four experiments. Immunoblot with anti- 
ubiquitin antibody is shown. M, molecular weight marker.
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Figure 23
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Immunoblots using anti-MBP antibody. A) Anti-MBP immunoblot of the purified MBP-TRIM fusion 
proteins. The full-length MBP-TRIM proteins and their molecular weight are indicated. B) Anti-MBP 
immunoblot of the in vitro ubiquitylation reactions described in the text and revealing the extent of 
self-ubiquitylation. The results with MBP-TRIM1, MBP-TRIM11, MBP-TRIM18 and MBP-TRIM32 
perfectly matched what observed with the anti-ubiquitin antibody (Figure 4M) indicating that self- 
ubiquitylation is mainly occurring. This is not the case with MBP-TRIM9 and MBP-TRIM27 where I 
detected reduced self-polyubiqutylation. C) Anti-MBP immunoblot of the ubiquitylation reactions of 
TRIM32 with the UBE2N/V1 complex. All the In vitro Ubiquitylation assays shown were repeated four 
times for all the TRIM proteins tested in the same order reported in the picture above that is 
representative of all the four experiments. Immunoblot with anti-ubiquitin antibody is shown. M, 
molecular weight marker.
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4.4 In vivo Ubiquitylation assay
Since in vitro ubiquitylation assays determined the E3 activity of the 
TRIM proteins tested, this raises the question of whether TRIM proteins 
could act as E3 ligases in mammalian cells. To evaluate TRIMs’ ability to 
induce self-ubiquitylation in mammalian cells, I performed in vivo 
ubiquitylation assays using the six selected TRIM proteins both as full-length 
and as UBE2 binding incompetent RING deleted forms. Indeed, as already 
observed for in vitro ubiquitylation assays, self-ubiquitylation is an important 
determinant to define an E3 ubiquitin ligase. Usually, candidate E3 ubiquitin 
ligase is co-transfected together with ubiquitin in mammalian cells. Then, the 
E3 is immunoprecipitated with a specific antibody and immunoblotting 
performed with the anti-ubiquitin antibody shows the ubiquitin chain(s) 
attached to the E3.
MycGFP-tagged wild-type TRIM1, 9, 11, 18, 27, 32 and their RING 
deletion mutants were co-transfected in HEK293T cells together with HA- 
tagged ubiquitin. TRIM proteins were immunoprecitated with the anti-Myc 
antibody and analyzed by western blotting using either an antibody against 
the HA tag to detect ubiquitylated proteins (Figure 24a, upper panels) or an 
antibody against the Myc tag to check for total immunoprecipitated MycGFP- 
TRIM proteins (Figure 24a, lower panels). Immunoblotting using anti-HA 
showed a high molecular weight (HMW) smear for each TRIM protein tested, 
suggesting that they are self-polyubiquitylated and/or that proteins co- 
immunoprecipitating with them are polyubiquitylated in mammalian cells 
(Figure 24a, left upper panels). Interestingly, mainly in the case of TRIMl, 
immunoblot with anti-HA reveals the presence of a strong single band at 
expected MycGFP-TRIMl molecular weight. This could highlight an 
exclusive TRIMl monoubiquitylation in HEK293T cells.
In contrast, the ubiquitylation observed in the presence of the 
corresponding RING-deleted mutant was extremely weak suggesting that the 
HMW species were likely produced mainly through the TRIM protein E3
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activity (Figure 24a, left upper panels). The residual faint ubiquitylation 
observed in correspondence of the RING-deleted TRIM protein might be due 
to the activity of the endogenous TRIM protein or of other E3 ligases. This 
still undefined endogenous E3 activity appears to be more relevant in the case 
of TRIM27 where even in the presence of the RING-deleted form a 
comparable polyubiquitylation was observed. Moreover, HEK293T cells 
transfected with HA-ubiquitin, either alone or with MycGFP-empty vector, 
produced no ubiquitylated species upon anti-Myc immunoprecipitation 
(Figure 24b).
To determine whether the observed in vivo ubiquitylation was mainly 
associated to proteasome-mediated degradation, the experiments described 
above were also performed in the presence of the proteasomal inhibitor 
MG 132. Treatment with MG 132 increased both the ubiquitylation (Figure 
24a, right upper panels) and the total amount of the TRIM proteins tested 
(Figure 24a, right lower panels). Interestingly, this treatment clearly 
increased also the ubiquitylation of TRIM27 and TRIM32 RING deletion 
mutants suggesting that other E3 ligases are implicated in their ubiquitylation.
Thus, these results indicate that, although to different extent, the TRIM 
proteins act as RING-dependent ubiquitin E3 ligase in mammalian cells.
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E3 ligase activity of TRIM proteins in HEK293 cells. A) In vivo ubiquitylation assay of 
MycGFP(MGFP)-tagged TRIM l, TRIM9, TRIM11, TRIM18, TRIM27 and TRIM32 full-length (FL) 
and RING deleted (AR) forms in HEK293T cells in the presence of HA-ubiquitin (HA-Ub) as 
indicated. Immunoblot of the anti-Myc immunoprecipitates using anti-HA antibody to detect 
ubiquitylated proteins (upper panels) and anti-Myc antibody to detect TRIM proteins (lower panels) 
are shown. Where indicated, cells were treated with the MG132 proteasomal inhibitor for six hours. 
Asterisks indicate expected TRIM proteins molecular weights. B) HEK293T cells transfected with HA- 
Ubiquitin either alone or together with MycGFP-pcDNA3 vector were immunoprecipitated with anti- 
Myc antibody. Legend as in A). All the In vivo Ubiquitylation assays were repeated three times for 
each TRIM protein tested. The picture reported above is representative of all the three experiments 
repeated for every TRIM protein selected.
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4.5 Specific TRIM-UBE2 binding occurs in HeLa cells
How selection and usage of UBE2 enzymes is achieved and what are the 
consequences on TRIM activity within the cellular context is a more 
complicated issue to address. In vivo selection may depend on a variety of 
parameters including the spatial accessibility of the E2 enzyme.
To address this issue, the subcellular distribution of the TRIM proteins and 
their interacting UBE2 enzymes was investigated by immunofluorescence 
after transfection of GFP- and HA-tagged constructs in HeLa cells. As 
already reported, TRIMl, 9, 11, 18, 27, and 32 were mainly localized in the 
cytoplasm of HeLa cells either in filamentous or speckled structures 
(Reymond, Meroni et al. 2001). UBE2D1, D2, D3, G2, N, V I, and V2 were 
diffused in both nucleus and cytoplasm (Figure 25a and Figure 26a). The 
only exception was UBE2E1, which is a strictly nuclear protein (Plafker, 
Plafker et al. 2004). When co-transfected with TRIM proteins, the UBE2 
enzymes generally maintained their distribution and were not apparently 
enriched in the TRIM defined cellular structures consistent with the fact that 
several of them are shared by many E3 ligases.
However, one exception was observed with the UBE2G2 and TRIM9 
partnership. As already shown (Reymond, Meroni et al. 2001), TRIM9 is 
present in cytoplasmic speckles while GFP-UBE2G2 is diffused in both the 
nucleus and the cytoplasm (Figure 25a). When co-transfected with TRIM9 in 
HeLa cells, a fraction of UBE2G2 was clearly recruited into TRIM9 
cytoplasmic speckles as also demonstrated by a collection of multiple focal 
planes (z-stack) (Figure 25b). Consistent with TRIM-UBE2 interaction data, 
when HeLa cells were co-transfected with HA-TRIM9 and GFP-UBE2D2, 
the latter conserved its diffuse distribution in the cell and it was not recruited 
by exogenous TRIM9, supporting the specific effect on UBE2G2 (Figure 
25c). To clarify if other TRIM proteins were able to exert the same effect on 
UBE2G2, I also transfected HeLa cells with GFP-UBE2G2 and either HA- 
tagged TRIMl, TRIMl 1, TRIM18, TRIM27, or TRIM32. UBE2G2 was not
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recruited by TRIMl, TRIMl 1, TRIM 18 and TRIM32 into any defined 
structures further supporting the specificity of what observed with TRIM9. 
Interestingly, even if TRIM27 formed cytoplasmic speckles like TRIM9, the 
UBE2G2 protein was never found within these structures (Figure 25d).
Moreover, I also observed that TRIM32 changed its own localization when 
co-transfected with either UBE2N or UBE2V2 proteins. In agreement with 
the literature (Reymond, Meroni et al. 2001), TRIM32 was localized in 
cytoplasmic perinuclear speckles, whereas UBE2N and UBE2V proteins were 
diffused within the cytoplasm and the nucleus (Figure 26a). When co­
transfected with GFP-UBE2N and HA-TRIM32,40% of HeLa cells showed a 
perfect co-localization of TRIM32 and UBE2N in the nucleus (Figure 26b, 
upper panels). In 60% of the cells I observed TRIM32 localized in well- 
defined speckles around the nucleus whereas UBE2N was diffused in both the 
nucleus and the cytoplasm (Figure 26b, lower panels). The peculiar 
TRIM32-UBE2N reciprocal localization was not observed when HeLa cells 
were co-transfected with GFP-UBE2N and HA-TRIM 18 that we previously 
found to interact (Figure 26f). When we transfected HeLa cells with HA- 
TRIM32 and GFP-UBE2V1, the latter was partially recruited in TRIM32 
speckles around the nucleus (Figure 26c). Curiously, although few cells were 
co-transfected with HA-TRIM32 and GFP-UBE2V2 (approximately 30%), I 
found a complete co-localization of the two in a diffused UBE2V2-like 
manner (Figure 26d). Consistently, the specific TRIM32/UBE2N and 
TRIM32/UBE2V2 localization was observed also when I trasfected HeLa 
cells with GFP-TRIM32 and HA-UBE2N/UBE2V2 (Figure 26e).
Thus, immunofluorescence experiments indicate that binding of several 
E2-TRIM pairs very likely occurs also in vivo.
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Figure 25
A
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TRIM9 co-localizes with UBE2G2 in cytoplasmic speckles. A) Immunofluorescence of HeLa cells 
transfected with either GFP-TRIM9 (left panel) or GFP-UBE2G2 (right panel). B) 
Immunofluorescence of HeLa cells co-transfected with GFP-UBE2G2 (left panel) and HA-TRIM9 
(middle panel). The right panel represents the overlay of left and middle images. The inset shows a 
lateral view of the above cell as resulting from a z-stack collection of confocal images.
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UBE2G2 does not colocalize with TRIM l, TRIM11, TRIM18, TRIM27 and TRIM32. 
Immunofluorescence of HeLa cells co-trasfected with GFP-UBE2G2 (left panels) and HA-TRIM1, HA- 
TRIM11, HA-TRIM18, HA-TRIM27, HA-TRIM32 (middle panels). The right panels represent the 
overlay of left and middle image
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Figure 26
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TRIM32 co-localize with UBE2N, VI, V2 proteins. A) Immunofluorescence of HeLa cells single 
transfections with: GFP-TRIM32, HA-UBE2N, GFP-UBE2V1, GFP-UBE2V2. B) Immunofluorescence 
of HeLa cells co-transfected with GFP-UBE2N (left panels) and HA-TRIM32 (middle panels). The 
right panels represent the overlay of left and middle images. Two behaviours of TRIM32 in the 
presence of UBE2N are represented and their percentage shown (40% in the upper panel; 60% in the 
lower panel). C) Immunofluorescence of HeLa cells co-transfected with HA-TRIM32 (left panel) and 
GFP-UBE2V1 (middle panel). The right panels represent the overlay of left and middle images. D) 
Immunofluorescence of HeLa cells co-transfected with HA-TRIM32 and GFP-UBE2V2. Legend as in 
C).
IGFP-U8E2N HA-TRIM 32
HA-TWM32
110
F
GFP-UBE2N HA-TKM13 Merge
E) The same experiment shown in Figure 4Q(b)-4Q(d) of the main text performed with the 
reciprocally tagged constructs as indicated (GFP-TRIM32 and HA-UBE2N, VI and V2). F) The same 
experiment shown in Figure 4Q(b)-4Q(d) of the main text using GFP-UBE2N and HA-TRIM18.
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4.6 TRIM proteins involvement in SUMOylation pathway.
4.6.1 TRIM proteins interaction with UBE2I
To further investigate TRIM proteins involvement in SUMOylation 
pathway, I started to test interaction between TRIM proteins and UBE2I, 
which is the specific SUMO UBE2 enzyme (see Introduction), through the 
Interaction Mating technique. Then, as already shown in paragraph 4.2, I 
investigated the interaction between a sub-group of the TRIM protein family 
and the UBE2I enzyme through MBP-pull down assay. It is well known the 
involvement of TRIM19/PML in the SUMOylation pathway that has a key 
role in the organization of PML-Nuclear Bodies (Zhong, Muller et al. 2000). 
Indeed, recently Chu and Yang (2010) demonstrated that some TRIM family 
members can efficiently interact with UBE2I and strongly enhance transfer 
SUMO 1-3 from UBE2I to Mdm2, p53 E3 Ubiquitin Ligase (Chu and Yang 
2011).
1. Interaction Mating assays
I tested the 42 TRIM proteins listed in TABLE 3 expressed both as bait 
and as prey in the yeast EGY48 (mating type a) and in the yeast strain 
EGY42 (mating type a) against UBE2I protein expressed in both vectors and 
yeast strains. To be certain of the interactions observed, I repeated the 
Interaction Mating assays seven times and every time, before performing the 
Interaction Mating experiments, I freshly transformed TRIM and UBE2I 
pEG202 and pJG4-5 constructs in yeast strain (see paragraph 3.2.1). I 
summarized the results of the Interaction Mating assays in TABLE 4.
These data revealed that the majority of the TRIM proteins tested 
interact with UBE2I enzyme suggesting a putative involvement of the TRIM
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proteins in the SUMOylation pathway either as SUMO E3 Ligases or as 
SUMO substrates, or both.
Contrary to that demonstrated for TRIM/UBE2 interactions (see 
paragraph 4.1.4), interaction was observed also between the “unorthodox” 
TRIM members that lack the RING domain (Sardiello, Cairo et al. 2008) and 
the UBE2I enzyme, with TRIM44 being the only exception (Figure 27b). 
Consistently, Interaction Mating assays performed with TRIM 18 and 
TRIM32 mutant constructs lacking the RING domain and UBE2I, maintained 
interaction between the TRIM proteins and the UBE2I enzymes (Figure 27a). 
These data confirmed the recent report demonstrating that both RING and B- 
box domain are necessary for TRIM19/PML to act as E3 SUMO Ligase (Chu 
and Yang 2011).
This indicates that in some instances the RING domain is not necessary 
for the binding of TRIM proteins to the UBE2I enzyme.
2. MBP pull-down assays
Then, I verified the interactions between the six above selected TRIM 
proteins (TRIMl, TRIM9, TRIMl 1, TRIM18, TRIM27, TRIM32) and 
UBE2I enzyme through MBP pull-down assays.
MBP-TRIM fusion proteins immobilized on the beads were incubated 
with HEK293T crude lysates transiently expressing MycGFP-UBE2I and 
specific binding was revealed by immunoblot (Figure 28a). MBP-pull down 
assays showed that all the TRIM proteins tested captured UBE2I, confirming 
the interactions observed in yeast, albeit with different binding affinities. 
Although the MBP pull-down technique is not able to determine the kinetic 
and energetic parameters governing the interactions between the proteins 
tested, TRIM27 and TRIM32 showed stronger binding to UBE2I (Figure 
28a), whereas TRIM9 showed a weaker one (Figure 28a). As expected, no 
binding was observed between MBP protein and UBE2I enzyme.
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Thus, taken together these data confirmed the interactions observed in 
yeast Interaction Mating between the selected TRIM proteins and UBE2I with 
an apparent different binding. Moreover, these data have to be considered 
preliminary and they will require validation by other techniques.
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TABLE 4
H om o-interaction UBE2I
TRIMl X X
TRIM2 X
TRIM 3 X X
TRIM4 X
TRIM 5 X X
TRIM6 X X
TRIM7 X X
TRIM8 X X
TRIM9 X X
TRIM 10 X X
TRIM 11 X X
TRIM 12 X X
TRIM13 X
TRIM14* X X
TRIM 15 X
TRIM16* X X
TRIM17 X X
TRIM18 X X
TRIM 19 X X
TRIM20* X X
TRIM21
TRIM22
X X
TRIM23
TRIM24
TRIM25
TRIM26
X X
TRIM27
TRIM28
X X
TRIM29* X X
TRIM30 X X
TRIM31 X
TRIM32 X X
TRIM37 X X
TRIM39
TRIM40
TRIM42
TRIM43
X X
TRIM44* X
TRIM45
TRIM46
TRIM48
X
TRIM50 X X
TRIM52 X
TRIM proteins interact with UBE2I enzyme. List of the results obtained with the binary two- hybrid 
system. The TRIM and the UBE2I are indicated. The asterisk and the red colour indicate the RING- 
less TRIM proteins. TRIM proteins homo-interaction is used as internal control.
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MBP-pull down assays confirm the interactions observed between TRIM proteins and UBE2I enzyme.
A) MBP-pull down analysis of MycGFP-UBE2I transiently expressed in HEK293T cells with six MBP- 
TRIM proteins (TRIMl, TRIM9, TRIMl 1, TRIM18, TRIM27, TRIM32). MBP was used as control. 
Immunoblot with the anti-Myc antibody of 1/5 of the input lysates is shown in the upper panel; 
immunoblot with the anti-Myc antibody of 1/2 of the input lysates is shown in the lower panel. B) 
Coomassie Blue staining gels of the MBP-TRIM proteins linked to amylose beads are shown. Red 
asterisks indicate MBP and MBP-TRIM proteins molecular weight. This experiment was repeated 
three times in the same order reported in the picture above that is representative of the results 
obtained.
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4.6.2 In vitro SUMOylation assays
TRIM interaction with UBE2I raised the question of whether TRIM 
proteins could be also modified by SUMO peptides. To address this issue, I 
performed in vitro SUMOylation assays. SUMOylation reaction is performed 
by mixing all SUMOylation pathway components: ATP, recombinant El 
(SAE1/2), recombinant E2 (UBE2I), the putative substrate and either SUMOl 
or SUM02. The most important difference between an in vitro ubiquitylation 
assay and an in vitro SUMOylation assay is that the former reveals the role as 
E3 Ubiquitin Ligase of the protein tested thanks to its ability to form poly- 
ubiquitylation species when added to the reaction mixture; the latter mainly 
highlights the possibility of the protein tested to be SUMOylated since the 
UBE2I enzyme can attach poly-SUMO chains to a substrate (Bernier- 
Villamor, Sampson et al. 2002).
The above 6  MBP-TRIM proteins were incubated in the reaction 
mixture as indicated above. The immunoblot analysis of the reaction products 
using antibodies against SUMOl revealed the presence of poly-SUMO 1 
species when the recombinant MBP-TRIM protein was added to the reaction 
mixture (Figure 29a). Interestingly, the immunoblot analysis of the reaction 
products against SUM02 revealed the presence of the poly-SUM02 species 
only when the recombinant MBP-TRIM27 was added to the reaction mixture 
(Figure 29b). In both cases GST-PML was used as experimental control.
Thus, taken together these preliminary data further demonstrate that 
TRIM proteins can participate in the SUMOylation pathway in a very specific 
manner acting either as substrate or as E3 SUMO ligase or both.
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In vitro SUMOylation assays. A) MBP-TRIM proteins (TRIMl, TRIM9, TRIMl 1, TRIM18, TRIM27, 
TRIM32) were tested through in vitro SUMOylation experiments (SUMOl). As control, the assay was 
performed without SUMOl peptide (lanes with the TRIM indicated). Immunoblot with anti-SUMOl 
antibody to detect the poly-SUMOylated species is shown. GST-PML is used as experimental control. 
The experiment was repeated four times in the same order reported in the picture above that is 
representative of the results obtained.
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B) MBP-TRIM proteins (TRIMl, TRIM9, TRIMl 1, TRIM18, TRIM27, TRIM32) were tested through 
in vitro SUMOylation experiments (SUM02). As control, the assay was performed without SUM 02 
peptide (lanes with the TRIM indicated). Immunoblot with anti-SUM02 antibody to detect the poly- 
SUMOylated species is shown. GST-PML is used as experimental control. The experiment was 
repeated four times in the same order reported in the picture above that is representative of the results 
obtained.
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CHAPTER 5: DISCUSSION
In my study I demonstrated that TRIM proteins are able to interact with 
Ubiquitin Conjugating Enzyme (UBE2) and are therefore likely to be 
implicated in the ubiquitylation process acting as a class of Ubiquitin Ligase 
or E3.1 have also found that the majority of the TRIM proteins tested interact 
with UBE2 enzymes with a defined specificity that is maintained in their 
ability to act as E3 Ubiquitin ligases. Moreover, I have examined the 
involvement of TRIM proteins in the SUMO pathway, the best known among 
the Ubiquitin-like pathways (UBLs), and I have also demonstrated that TRIM 
proteins might partake in the process either as SUMO substrate or as E3 
SUMO Ligases or both.
A direct interaction between UBE2 and E3 enzymes is required for the 
ubiquitin ligase reaction. However, the modest affinity and transient nature of 
E2/E3 complexes pose additional technical challenges for the identification of 
E2/TRIM pairs. Standard techniques based on affinity purification of bait 
protein, such as co-immunoprecipitation, rarely succeed due to the weak 
affinity of the complexes.
Co-immunoprecipitation is a very useful method to co-purify interacting 
protein partners. The success of this strategy depends on the availability of 
good-quality antibodies directed against the target protein. In addition, since 
this procedure involves a single purification step, this limits the use of this 
strategy for protein present in very low abundance. A strength of the co- 
immunoprecipitation strategy is, however, that proteins associated in vivo are 
copurified in a rapid and simple manner. Therefore, co-immunoprecipitation 
remains a rigorous method to validate the physiological significance of 
protein interaction. Consistent with the co-immunoprecipitation technique, 
pull-down assays should be used both to confirm protein-protein interactions 
predicted by other methods (i.e. co-immunoprecipitation, yeast two hybrid) 
and as initial screening assay for purifying unknown protein-protein
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interactions. Pull-down assays are a form of affinity purification and are very 
similar to the co-immunoprecipitation except that a bait protein is used 
instead of an antibody. The most important limitation in the usage of the pull­
down assays is the nature of the protein-protein interactions. Indeed, stable 
protein-protein interactions are easy to be isolated because the complex does 
not disassemble over time. Strong, stable protein complexes can be washed 
with high-ionic strength buffers to eliminate any false-positive results. If the 
protein-protein interaction is a transient one like E2/E3 pairs, the specific 
interaction is difficult to identify because the complex may dissociate during 
the assay and it could generate false negative interactions.
Recently, a new strategy for protein complex purification and for 
identification of interacting protein partners has been developed: the Tandem 
Affinity Purification (TAP). TAP involves the fusion of a protein tag to the 
target protein and its expression in host cell or organism. The purified 
material can then be fractionated on a gel, and co-purified proteins can be 
identified by mass spectrometry or Edman degradation. TAP strategy 
combines several advantages of the standard biochemical purification and the 
co-immunoprecipitation strategies like rapid, selective, and efficient recovery 
of the in v/vo-associated target complex from the extract. Although the TAP 
method is broadly applicable, there are some important limitations. First, a 
functional TAP-tagged protein must be made. For some protein, tagging at 
both the amino and the carboxyl termini of the protein may affect its activity. 
Second, some proteins may contain an endogenous TEV protease cleavage 
that may interfere with protein purification. However, to better characterize 
the interactions of purified proteins, many techniques have been developed. 
Among these the label-free of protein-protein interaction at solid surface by 
Surface Plasma Resonance (SPR) is the most powerful. The most important 
advantage of this technique is the measurement in real-time of the kinetics of 
ligand-receptor interactions that facilitates SPR’s application in label-free 
quantitative immune-assay techniques for proteins and small analytes, in
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conformational studies of protein as well as in the real-time association- 
dissociation measurements of ligand-receptor interactions. However, SPR 
biosensors usually lack the sensitivity to detect the interaction of protein with 
small ligand and due to its inability to handle many samples simultaneously, 
they are unsuitable for use in high throughput applications.
Indeed, to screen a large number of protein-protein interactions, Yeast Two 
Hybrid and Protein Fragment complementation (PCA) are the elective 
methods. In particular, Y2H was inspired by the modular structure of 
transcription factors containing a DNA-binding domain (DBD) and a 
transcription activation domain (AD). Splitting the DBD and the AD 
inactivated the transcription factor, while its function could be restored fusing 
DBD and AD to two interacting proteins. The Y2H utilizes this effect to 
identify protein interactions by fusing a “bait” protein to a DBD and potential 
interaction partners (“prey” proteins) to the AD. Numerous variations of Y2H 
have been developed including systems with several reporter genes, one- 
hybrid and three-hybrid systems for identifying proteins interactions with 
DNA and RNA (Fashena, Serebriiski et al. 2000; Causier 2004). Even if the 
Y2H approach has many advantages like high specificity and quickness, it 
also has many disadvantages like: small overlap between Y2H experiments; 
the use of sequence chimeras can impose difficulties since fusion can change 
the structure of a target protein. In addition, protein folding and 
posttranslational modifications can differ between yeast and other organisms. 
The classical Y2H systems are limited to protein interactions in the nucleus; 
thus interactions involving proteins integrated into or anchored to the plasma 
membrane are barely accessible. This dilemma was resolved by extending the 
Y2H approach to the PCA assays that were implemented in the split ubiquitin 
technique. Other enzymes, such as adenylate cyclase or an anthranilate 
isomerase have been used for split-protein-based screening of protein 
interactions in different organisms. A common feature of these approaches is 
the indirect and time-shifted response, as they rely on the transcription of the
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reporter gene. Another general approach related to PC A is based on protein 
splicing and has been applied to several reporter proteins, such as GFP and 
firefly luciferase. Although Y2H and PC A are potent techniques for 
identifying interactions, the real-time monitoring and localization of protein 
interactions in living-cells requires a direct spectroscopic investigation. To 
date, the most powerful technique for the direct spectroscopic detection and 
monitoring of protein interactions in living cells is fluorescence resonance 
energy transfer (FRET). The detection of protein interactions in living cells 
by FRET can be carried out conveniently and with high throughout by flow 
cytometry. However, FRET technique is limited by the relatively high 
background of cellular autofluorescence as well as by the direct excitation of 
the fluorescence acceptor, which frequently biases the interaction 
experiments. Since the high number of false positive generated by Y2H, PC A 
or FRET techniques, all the protein-protein interactions detected need to be 
confirmed through other techniques like co-immunoprecipitation, pull-down 
or TAP.
Thus, taken together all the information about the techniques generally used 
to detect protein-protein interactions, I decided to screen all the putative 
interactions between TRIM proteins and UBE2 enzymes through the Yeast 
Interaction Mating technique since it has been somewhat more successful in 
identifying E2/E3 pairs, presumably because a positive read-out can be 
obtained even for transient interactions. Indeed, two large-scale Y2H screens 
for E2 partners have been reported. A screen that utilized full-length E2s as 
bait against circa 150 RING-protein preys yielded putative partners for all but 
two of 39 E2s (Cdc34 and Birc6 ) and for approximately 90 of the E3 preys 
(Markson, Kiel et al. 2009). Instead, a screen of over 250 RING domain preys 
with 36 E2 Ubc domain baits failed to identify a binding partner for ten E2s 
that are known to conjugate Ub and fewer than half the RING domains 
returned a positive E2 interaction (van Wijk, de Vries et al. 2009). The 
different outcomes in the screens may be due in part to the use of full-length
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versus specific E2 and E3 domains, consistent with emerging evidence for 
non-canonical E2/E3 interactions. However, the requirement of some RING 
E3s to exist as heterodimeric or multi-component complexes may further 
affect the attainable yield in a yeast Interaction Mating screen. For example, 
in a targeted Y2H screen aimed at identifying the human E2s that interact 
with the heterodimeric RING E3, BRCA1/BARD1, a bait construct in which 
the RING domains of BRCA1 and BARD1 were fused into a single 
polypeptide that folds correctly into the E3-active structure identified ten E2s 
that interact with BRCA1/BARD1 (Christensen, Brzovic et al. 2007). Screens 
using baits comprised solely of the BRCA1 RING failed to identify any E2s 
that have been shown biochemically to transfer Ub (Markson, Kiel et al. 
2009; van Wijk, de Vries et al. 2009). Within a Y2H screen, the E2 may or 
may not be conjugated to Ub, depending on whether the endogenous yeast El 
is able to charge the E2 of interest among other factors. Therefore, an issue 
that may contribute to a failure to identify E2s for an E3 in a Y2H experiment 
is that Y2H studies may only screen for interactions between an E3 and a free 
E2, although the functionally relevant interaction involves the E2~Ub 
conjugate. There are examples of E3s that show detectable binding only to an 
E2~Ub. For example, SspH2 (a bacterial protein with E3 ligase activity) binds 
only to an activated E2~Ub conjugate and not to the individual components 
(Levin, Eakin et al. 2010). It remains to be seen if this feature will be unique 
to bacterial E3s that have evolved via convergent evolution to work with host 
E2 enzymes or whether there are eukaryotic E3s that only bind to E2~Ub 
species. In any case, these examples demonstrate the complicated and 
context-dependent nature of E2/E3 interactions that confound the ability to 
identify them.
In all the seven Interaction Mating screens performed, I could observe that 
the majority of the TRIM proteins fulfil this rule and I detected more than 100 
interactions between UBE2 and TRIM proteins. As already observed with 
other ligases, in most cases TRIM proteins interact with more than one UBE2
125
enzyme and vice versa (van Wijk, de Vries et al. 2009). I believe that the 
TRIM proteins that cannot interact with any of the UBE2 proteins tested, 
might not be expressed in the yeast or may assume an improper conformation 
that may hide the DNA Binding or B42 domains. Consistently, the majority 
of the TRIM proteins that present no interactions with the UBE2 enzymes 
cannot homo-dimerize (Reymond, Meroni et al. 2001). It is also possible that 
in some cases TRIM proteins might not be able to interact with UBE2 at all or 
that they could interact with UBE2 enzymes not used in my experiments. 
Moreover, since for some TRIM proteins have been reported their ability to 
form hetero-complexes, it might be that hetero-interactions is an important 
requirement to act as E3 Ubiquitin Ligase.
Moreover, I have demonstrated that the RING domain mediates the 
interaction between the TRIM proteins and the UBE2 enzymes. I tested 
TRIM 18 and TRIM32 mutants carrying single domain deletions (RING, B- 
box, Coiled-coil, and RFP-like) and I demonstrated that deletion of the RING 
finger results in the loss of interaction with UBE2 proteins. Furthermore, an 
isolated RING finger domain, but not RFP or BB-CC domains, could interact 
with the UBE2 enzymes, confirming that the RING motif is necessary and 
sufficient for the interaction with the UBE2 proteins. The concept that this is 
the domain offering the surface for direct E2/E3 interaction is reinforced by 
the lack of UBE2 binding observed with the naturally occurring RING-less 
TRIM proteins (Sardiello, Cairo et al. 2008). My data also suggest that the B- 
boxes are not directly involved in this interaction. B-boxl and B-box2 are 
zinc-binding domains found within the tripartite module (Sardiello, Cairo et 
al. 2008) that assemble to form RING-like structure. Given this resemblance, 
it has often been speculated that the B-boxes might also interact with E2 
enzymes. Recently, Han et al. (2011) have demonstrated that MIDI/TRIM 18 
B-boxes support RING role in the ubiquitylation process (Han, Du et al. 
2011). In particular, they observed that MID1/TRIM18 B-boxl have a key 
role because it appears to amplify the E3 activity of the RING domain
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presenting additional lysine residues to be mono-ubiquitylated (Han, Du et al. 
2011). It is tempting to speculate that B-boxes have originally evolved to 
function as E3 ligases but now they may support RING domain.
As a general rule, the majority of the TRIM proteins tested 
preferentially interact with a subset of the 26 UBE2 enzymes, which is 
constituted by: UBE2D1, UBE2D2, UBE2D3, UBE2D4, UBE2N, UBE2E1, 
UBE2E2, and UBE2E3. On the other hand, they do not interact with 
UBE2L3/UBE2L6 enzymes indicating that the interaction between the TRIM 
proteins and the UBE2 enzymes is specific. Indeed, figure 5A shows a 
phylogenetic tree of 20 of the UBE2 proteins utilized in my experiments, 
which indicates that the subset of the UBE2 proteins that interact with the 
majority of the TRIM proteins is constituted by UBE2 enzymes that are 
evolutionary close to each other. The only exception is the UBE2I that is not 
closely related to the subset of the UBE2 enzymes indicated above. This 
UBE2 interacts with almost all TRIM and, since the UBE2I is the specific 
UBE2 involved in the SUMOylation process, this interaction may indicate 
that many TRIM proteins could be involved in this Ubiquitin-like (UBLs) 
process or it could be less specific because SUMO modified UBE2I, in yeast, 
may bind to SUMO Interacting Motif in the TRIMs. Instead, the 
UBE2L3/UBE2L6 enzymes, which do not interact with TRIM proteins, are 
distant in the phylogenetic tree from the subset indicated above (Figure 30). 
My data support a model in which the RING TRIM proteins that interact with 
the UBE2L3/UBE2L6 enzyme cannot interact with the UBE2D and E family 
and vice versa (Martinez-Noel, Muller et al. 2001).
In my experiments I also observed two important exceptions: TRIM9 
and TRIM32 that are the only ones that can interact with UBE2G2 and 
UBE2V1/UBE2V2, respectively. Given that the RING domain is involved in 
the interaction between these TRIM ones and the UBE2 proteins indicated 
above, I aligned the RING domain primary sequences of some TRIM proteins 
(Figure 31).
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Figure 30
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with any TRIM proteins
UBE2 proteins that interact with 
the majority of TRIM proteins
SUMO-E2 enzyme
□ UBE2 protein that interact exclusively with TRIM9
I UBE2 proteins that interact only 
J with TRIM32
A phylogenetic tree produced upon the alignment of the 20 UBE2 proteins tested. The majority of the 
TRIM proteins interact with a subset of UBE2 enzymes, i.e. UBE2D1, UBE2D2, UBE2D3, UBE2N, 
UBE2E1, UBE2E3, and UBE2I. These UBE2 proteins are very close within the tree and therefore are 
more similar to each other. None of the TRIM proteins that interact with the subset indicated above 
could interact with UBE2L3/UBE2L6 that seem to diverge from the subset of UBE2 indicated above.
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Figure 31
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□ TRIM9 domain sequence Some TRIM RING domain sequence
TRIM32 domain sequence
Alignment of some TRIM proteins RING motif. The majority of TRIM proteins has a very similar 
consensus of RING domain sequence. The only exceptions are TRIM9 and TRIM32 that are the only 
TRIM proteins, that interact with UBE2G2 and UBE2V1/UBE2V2 respectely.
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I could notice that TRIM9 and TRIM32 RING domains present peculiar 
sequence patterns. TRIM9 RING domain presents a second loop which is 
longer than the second loop of the other TRIM proteins; on the other hand 
both the first and the second loop of TRIM32 are shorter than the other ones. 
This observation supports the specificity of TRIM-UBE2 interactions 
determined by the RING sequence that probably translates into a slightly 
different structure.
I confirmed that the selected TRIM proteins behave in vivo as RING- 
dependent ubiquitin ligases with a major involvement in proteasome- 
mediated degradation. I also assessed the in vitro ubiquitin E3 activity of 
TRIM1, 9 ,11,18, 27, and 32 in the presence of the specific UBE2 enzyme(s) 
they interact with. The binding specificity between TRIM proteins and UBE2 
enzymes is perfectly translated in the ability to function as E3 ligases. I now 
provide a direct proof of TRIM ubiquitin ligase activity in vitro and of the 
identity of the UBE2 enzymes they use for this function: Dl-3, E l, N and, in 
the case of TRIM 11 also J2, but not L3 and L6 . Moreover, I assessed for the 
first time in vivo and in vitro E3 activity for TRIM1 and its attitude to use D l- 
3, El and N classes of UBE2 to exert this function. In the case of TRIM27, 
despite many biochemical findings as transcriptional and signalling regulator 
(Shimono, Murakami et al. 2000) few data on the E3 activity are available. 
Interestingly, differently from a recent report, I could observe the inability to 
interact and function with D2 (Gillot, Matthews et al. 2009).
One of the most specific functional interactions I assessed is between 
TRIM9 and UBE2G2. Interestingly, these two genes that are specifically 
expressed in the embryonic and adult nervous system further supporting their 
specific interaction (Berti, Messali et al. 2002) (www.genepaint.org). In the 
case of UBE2G2, structural and biochemical studies demonstrated that for its 
specific interaction with the gp78 E3 ligase an additional domain is required 
(Chen, Mariano et al. 2006) I still do not know if other regions of the TRIM9
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protein are implicated in these specific interactions. However, its RING 
sequence is peculiar as it presents an extended second loop if compared to the 
class D and E interacting TRIM proteins (Figure 31) (Sardiello, Cairo et al. 
2008). I could observe that overexpression of TRIM9 within the cells induces 
a relocalisation of UBE2G2 that is recruited in a specific manner in the 
TRIM9 cytoplasmic bodies. TRIM9 is a neuron specific component of a 
SNARE complex associated with synaptic vesicle release control (Li, Chin et 
al. 2001). UBE2G2 is one of the two E2 enzymes involved in endoplasmic 
reticulum-associated degradation (ERAD) (Chen, Mariano et al. 2006). It is 
tempting to speculate that TRIM9 might cooperate with UBE2G2 in the 
ERAD control of membrane-associated synaptic SNARE proteins destined to 
the secretory pathway.
TRIM32 ubiquitin E3 activity has been already reported on several 
physiological substrates (Albor, El-Hizawi et al. 2006). Consistent with my 
results, the above activity requires the presence of D and E classes of UBE2 
enzymes (Albor, El-Hizawi et al. 2006). Moreover, I added information on 
the activity with UBE2N to these data. Besides binding with the D, E and N 
types, I found that TRIM32 interacts in a very specific manner with UBE2V1 
and V2, which are catalytically dependent on the UBE2N for their function. 
Indeed, I found that TRIM32 is a more efficient E3 ligase in the presence of 
UBE2N/V1 than with UBE2N alone. Interestingly, so far no direct interaction 
has been reported between an E3 ligase and either UBE2V1 or V2. My data 
clearly show that not all the TRIM proteins observed to bind UBE2N also 
interact with UBE2V1 and V2 stressing the peculiar ability of TRIM32 in 
these interactions. The immunofluorescence experiments show that TRIM32 
and the aforementioned UBE2 enzymes change their reciprocal localisation 
within HeLa cells further suggesting that also in vivo TRIM32 may take 
advantage of the use of UBE2V1 and V2 for its activity. Noteworthy, the 
hetero-dimer UBE2N/V1 is specifically involved in NFkB pathway, the same
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in which TRIM32 also participates through its ability to control Piasy 
degradation (Albor, El-Hizawi et al. 2006-.
TRIM proteins’ involvement in different cellular process such as regulation 
of cell cycle and division, transcriptional regulation, differentiation and 
development, apoptosis, DNA repair, regulation of the immune and 
inflammatory responses have been reported (Meroni and Diez-Roux 2005). 
Since many of these cellular processes have as critical regulators the 
Ubiquitin-like proteins (SUMO, ISG15, Nedd8  and Atg8 ), my study also 
provided preliminary data about TRIM proteins’ involvement in 
SUMOylation pathway. I tested interaction between TRIM proteins and 
UBE2I, which is the exclusive SUMO-Ubiquitin Conjugating Enzyme, again 
by the Interaction mating technique. I found that the majority of the TRIM 
proteins tested interact with UBE2I/Ubc9 and that RING domain is not 
closely involved in TRIM/UBE2I interaction. Recently Y Chu and X Yang 
(Chu and Yang 2011) have indicated TRIM proteins as a new class of SUMO 
E3 Ligase. In their study they also demonstrated that TRIM SUMO E3 
activity relies on both the RING domain and intact B l- and B 2-boxes. 
Although speculative, it is possible that TRIM protein may also attach 
ubiquitin and SUMO on the same protein target simultaneously or 
sequentially by using different protein domain.
SUMOylation differ from both Ubiquitylation and other Ubiquitin-like 
pathways because the UBE2I can attach polySUMO 1/2/3 chains to the 
substrate without E3 enzymes, albeit with lower efficiency. I further 
performed in vitro SUMOylation assay on a selection of TRIM proteins 
whose interaction with UBE2I was previously confirmed by the MBP-pull 
down assay. I found that all TRIM proteins tested (TRIM1, TRIM9, TRIM 11, 
TRIM18, TRIM27, TRIM32) act as both/either SUMO ligase and/or substrate 
by adding SUMOl to the reaction mixture; on the contrary only TRIM27 act 
as either SUMO ligase or substrate or both with SUM02. These data are 
supported by TRIM27 specific binding to PML/TRIM19, that has been
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proposed to have an E3 SUMO 1/2 ligase activity located to its RING domain. 
Moreover, between the subgroup of TRIM proteins selected, TRIM27 is the 
only one that localizes in the nucleus and, in particular, in the Nuclear Bodies 
(NBs) where SUM02 is abundant. It is tempting to speculate either that 
TRIM proteins may act as E3 Ubiquitin Ligase whose activity is regulated by 
SUMOylation or that TRIM proteins may act as a novel class of E3 Ubiquitin 
and SUMO Ligase involved in the regulation of many cellular processes. 
Conclusively assessing the in vivo role of the TRIM proteins, however, will 
require further efforts. Interaction with more than one UBE2 enzymes may 
underline their consecutive usage, especially when D and E classes are 
concerned, and the formation of different chains of specific linkage. Thus, a 
single TRIM may have dual or more E3 activity with a consequent 
involvement in different cellular process. As example, my screens underline 
the ability of TRIM32 to bind both UBE2D enzymes that are involved in K48 
poly-ubiquitin chain formation, and UBE2N/V1-UBE2N/V2 complexes that 
are both involved in K63 poly-ubiquitin chain formation. It is presumable a 
dual role for TRIM32: on a hand regulation of some cellular processes 
through protein specific degradation, on the other hand activation of specific 
intracellular pathways (i.e. DNA repair and activation of NF-kB). Candidate 
E2 enzymes identified as interacting with TRIM32 must be followed up in 
vitro ubiquitylation study using ubiquitin mutants (i.e. K48 and K63 ubiquitin 
chain mutants) to better investigate TRIM32 biological role and to confirm a 
different effect on its E3 function. Of course, it could be useful repeating the 
same analysis for all the TRIM proteins selected for my PhD work.
It is well assessed that TRIM E3 ligases function in diverse processes in the 
cell. The biological role of many TRIM proteins, however, is still obscure and 
an important aspect in understanding E3 ligase function is to identify the 
biological context in which they function and their physiological substrate(s). 
Even if my work gives an important indication for putative TRIM biological 
role thanks to their selective usage of specific UBE2 enzymes, it will be
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necessary to identify putative substrate(s) through Yeast Two hybrid or RNAi 
screen. Consequently, it must verify if TRIM proteins preferentially use the 
UBE2 identified in my screening for either auto-ubiquitylation or substrate 
ubiquitylation or both to better understand mechanism inside TRIM/E2 
interactions.
Detailed structures have been solved for E2/E3 complex and amino acid 
residues responsible for these interactions have been identified. Moreover, 
more detailed information are available regarding UBE2 amino acid residues 
than E3’s ones. It might be interesting to assess putative TRIM/UBE2 
complex structure through Homology Modeling procedure comparing 
TRIM/UBE2 experimental three-dimensional structure with E3/E2 complexes 
already solved. Taken together all the data presumable collected may give 
important indication for the design of drugs that might block the 
ubiquitylation pathway in a selective way. Since the involvement of TRIM 
proteins in many pathological conditions from cancer to immunological 
disease, the modeling of drugs that are able to block in a specific way the 
pathway in which TRIM proteins are involved could give a good effort in the 
treatment of the specific diseases.
Finally, the screening of TRIM proteins for their cadre of interacting E2s will 
lead to further insight into the mechanisms of protein ubiquitylation. Some 
foreseeable areas that will benefit include: identification of more E3s that 
function with the ubiquitin-like proteins, development of predictive models 
guiding E2 selection by an E3, and ideally, the ability to thoroughly 
investigate E3-dependent substrate ubiquitylation.
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